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Fumonisin B1 (FB1) is a mycotoxin which is well characterised as a contaminant of maize and 
maize-based products worldwide, especially in South Africa. Its toxic effects have been associated 
with hepatotoxicity, nephrotoxicity and carcinogenicity. Tissue transglutaminase (TG2) is a unique 
and ubiquitous enzyme that catalyses the post-translational modification of proteins and has GTPase 
activity. Tissue transglutaminase is an important enzyme in a number of biological processes such 
as cell differentiation and proliferation, extracellular matrix organisation, cell signalling and 
apoptosis. This study investigated the possible role of TG2 induction by FB1 and the effect FB1 
toxicity has on the endoplasmic reticulum (ER) stress pathway in HepG2 cells. A SDS-PAGE 
adaption of the TG2 activity assay confirmed TG2 crosslinking activity by FB1 incorporation into 
fibronectin in the presence of calcium and TG2. This interaction was validated using fluorescent 
microscopy where FB1 incorporated into the HepG2 cell’s cytoplasmic vesicles and plasma 
membrane. The up-regulation of TG2 in HepG2 cells treated with FB1 was further investigated 
using western blotting and showed increased TG2 up-regulation. Fumonisin B1 disrupts membrane-
bound sphingolipids as a mechanism of toxicity; FB1 was shown to cause cytoskeletal damage and 
disrupted the cell’s membranes leading to cell stress. The protein kinase RNA-like endoplasmic 
reticulum kinase (PERK) ER stress pathway was induced as a result of FB1 exposure and 
investigated using western blotting and quantitative polymerase chain reaction. After 72hours with 
50µM and 100µM FB1 total PERK decreased, phosphorylated eukaryotic initiating factor α 
remained activated with a significant increase in messenger RNA (mRNA) expression (p<0.05) and 
transcription factor CCAAT-enhancer-binding protein homologous protein mRNA was significantly 
induced (p<0.05). The involvement of nuclear factor kappa B (NFkB) and TG2 in ER stress 
induced apoptosis was investigated through western blotting and quantitative polymerase chain 
reaction. After 72hours, an up-regulation of both nuclear NFkB and nuclear TG2 was observed; 
with a corresponding significant increase in nuclear TG2 mRNA expression (p<0.05). A significant 
ii 
 
increase in transcription factor, Sp1 mRNA expression (p<0.05) was observed after 72hours. Data 
suggests PERK activation leads to NFkB induction and nuclear translocation; which promoted 
nuclear TG2 transcription. The activation of TG2 resulted in Sp1 crosslinks that could act as 
potential inducers of FB1 induced apoptosis. Flow cytometry was used to measure apoptosis and 
mitochondrial depolarisation. Caspase activity was measured using the Caspase-Glo® assays and 
ATP concentration was measured using CellTitre-Glo
TM
 assay. After 72hours caspases 3/7 and 8 
showed a significant decrease in activity at 100µM FB1 (p<0.05) and a decrease in caspase 9. After 
72hours with 10µM FB1 treatment a significant increase in phosphatidylserine externalisation 
(p<0.05), a significant decrease in healthy/live cells (p<0.05) and a significant increase in 
depolarised mitochondria (p<0.05) were observed. There was also a significant increase in Sp1 
mRNA expression (p<0.05). However, at 50µM FB1 treatment there was a decrease in 
phosphatidylserine externalisation, a significant increase in live cells (p<0.05) and a significant 
decrease in depolarised mitochondria (p<0.05). Data suggests that ER stress persisted in HepG2 
cells with no apoptosis or cell recovery occurring at high chronic doses of FB1 whilst ER stress 
induced apoptosis at low chronic doses of FB1 in HepG2 cells. Fumonisin B1 may be a possible 
substrate for TG2 crosslinking activity due to its primary amine group, since this mycotoxin has the 
potential to induce TG2 expression and activation. Further studies are required to determine the role 
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In southern Africa, maize is a staple food source for a large number of the population, with an 
average consumption of 100kg/capita/year. This maize consumption represents more than 31% of 
total calories in SA (Smale et al. 2013). A fungi, Fusarium verticilliodes, is a common contaminant 
of maize and maize-based products both locally and worldwide (Grenier et al. 2012) and is known 
to produce secondary metabolites. These secondary metabolites are known as fumonisins with 
fumonisin B1 (FB1) being the most prevalent and toxic mycotoxin produced (Voss et al. 2007). It 
has been reported that South Africans are continuously exposed to low doses of FB1 with a daily 
dietary intake of 200μg/kg body weight (Domijan & Abramov 2011). This mycotoxin is an 
analogue of sphingoid bases and exerts its toxic effect through the competitive inhibition of 
ceramide synthase, which is important in the formation of complex sphingolipids (Voss et al. 2007). 
Sphingolipids play an important role in plasma membrane structure, cell growth regulation and in 
the transduction pathway where ceramide acts as a second messenger for a range of factors such as 
tumour necrosis factor (TNF)-α (Heidtmann-Bemvenuti et al. 2011; Soriano et al. 2005). A wide 
range of toxic effects have been associated with FB1 exposure, including hepatotoxicity and 
nephrotoxicity (Domijan & Abramov 2011), neural tube defects in foetus (Voss et al. 2007) and is 
most commonly associated with oesophageal cancers, where an increase in the incidence rate has 
been observed in Transkei and China (Nour et al. 2007). 
Tissue transglutaminase (TG2) is a ubiquitous enzyme located within the cytosol, nucleus and on 
the outer plasma membrane (Elli et al. 2009). These enzymes are responsible for the post-
translational modification of proteins through the insertion of an isopeptide bond between or within 
polypeptide chains. This transamidation reaction results from the acyl transfer between a ƴ-
carboxyamide glutamine residue (acyl donor) and a lysine Ɛ-amino residue of a primary amine (acyl 
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acceptor) which forms a proteinase-resistant covalent N-ƴ-glutamyl-Ɛ-lysyl-isopeptide bond 
(crosslink) (Griffin et al. 2002; Elli et al. 2009); with the crosslinked protein product being of higher 
molecular mass (Park et al. 2010). This reaction is calcium dependent because calcium binding is 
crucial for the induction of a conformation change within TG2 to expose the active site. Calcium 
activation however, can only occur at supraphysiological concentrations of calcium. The 
transcription of TG2 is regulated by retinoids, steroid hormones, cytokines and through methylation 
of its promoter region. This transcriptional regulation is time-dependent (Griffin et al. 2002). 
Cytokines such as TNF-α and stress molecule nuclear factor kappa B (NFkB) have been suggested 
to stimulate TG2 expression (Ientile et al. 2007). Where NFkB binds the tissue transglutaminase 
promoter gene (TGM2) directly and induces TG2 transcription (Ientile et al. 2007). The induction 
and activation of TG2 has been linked to increased apoptosis in rat hepatocytes (Fesus & Szondy 
2005); with widespread evidence for TG2 gene up-regulation during apoptosis (Griffin et al. 2002). 
According to Kuo et al. (2012), TG2 has been shown to be induced and activated as a result of 
endoplasmic reticulum (ER) stress via the protein kinase ribonucleic acid-like endoplasmic 
reticulum kinase (PERK) pathway and NFkB activation. After activation TG2 translocates to the 
nucleus via importin α3 (Kuo et al. 2011) where it crosslinks and inactivates specificity protein 1 
(Sp1), a general transcription factor that is responsible for the induction and expression of a proto-
oncogene for the hepatocyte growth factor receptor (c-Met). Increased TG2 activity therefore, leads 
to silencing of Sp1 and a decrease in expression of survival factors leading to apoptosis (Kuo et al. 
2011). 
 
The ER is a vast membranous organelle (Hotamisligil 2010), that is the site of synthesis, 
modification and trafficking of secreted and transmembrane proteins (Rutkowski & Kaufman 2004; 
Saito et al. 2011). Due to this central regulatory role of the ER, it is paramount for it to possess the 
ability to adapt its capacity to manage metabolic, synthetic and other adverse conditions 
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(Hotamisligil 2010). This adaptive capacity of the ER, is achieved by the quality control machinery 
in the ER which operates in concurrence with the protein folding pathways (Rutkowski & Kaufman 
2004). The increase in the accumulation of misfolded or unfolded proteins (UP) within the ER 
lumen, irrespective of endoplasmic-reticulum-associated protein degradation (ERAD) function, is 
sensed by resident molecules of the ER (Rutkowski & Kaufman 2004) and initiates the adaptive 
response known as the unfolded protein response (UPR) (Hotamisligil 2010). These resident 
molecules include three ER membrane-bound proteins: inositol-requiring protein 1α (IRE1α), 
PERK and activating transcription factor (ATF) 6; which act as UPR sensors that monitor the ER 
lumen for UP and transduce signals to the cytosol and nucleus. These three arms of UPR mitigate 
ER stress by suppressing protein synthesis, facilitate protein degradation and increase protein 
folding capacity of ER by increasing the production of protein chaperones (Hotamisligil 2010; Saito 
et al. 2011; Tam et al. 2012). Upon ER stress the PERK pathway is first activated, where PERK 
activation leads to the phosphorylation of serine 51 on eukaryotic initiating factor (eIF) 2α, which 
stimulates the translation of ATF4 messenger ribonucleic acid (mRNA) (Lasfargues et al. 2013). 
Activating transcription factor 4 controls selective pro-survival genes related to amino acid 
metabolism, redox balance, protein folding and autophagy as well as several micro ribonucleic 
acids (RNAs) that contribute to the inhibition of protein synthesis (Hetz 2012). A transcription 
factor CCAAT-enhancer-binding protein homologous protein (CHOP) is upregulated by ATF4 and 
is involved in ER stress-induced apoptosis (Lasfargues et al. 2013). The PERK- mediated eIF2α 
phosphorylation has also been linked to increased NFkB activation; where the attenuation of 
translation leads to a rapid decrease in inhibitor kappa (Ik) Bα, an inhibitor of NFkB, due to its 
relatively short half-life and the inhibition of its translation. This consequently leads to an 
accumulation of free and activate NFkB present within the cytosol. It was shown that the extent of 
translational attenuation is directly proportional to the level of active NFkB (Tam et al. 2012). 
Nuclear factor kappa B is an important regulator of inflammatory mediators such as TNF-α and 
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interleukin (IL) -6 (Hotamisligil 2010) as well as being a transcriptional inducer of TG2 (Ientile et 
al. 2007). 
Fumonisin B1 disrupts sphingolipid biosynthesis and therefore the plasma membrane, which could 
lead to the disruption of the cell and potentially cause ER stress and apoptosis. This study thus 




This study was conducted to determine: 
 
a) The effect of FB1 toxicity in the induction and catalytic activation of a calcium-dependent 
crosslinking enzyme TG2 in HepG2 cells. 
 
b) Whether FB1 exposure to HepG2 cells induces the PERK ER stress pathway as a 
mechanism of toxicity; with respect to TG2 activation. 
 
1.2 Hypotheses 
The following statements were hypothesised: 
 
a) Fumonisin B1 exposure would induce TG2 up-regulation and activation in HepG2 cells. 
 





2 LITERATURE REVIEW 
2.1 Fumonisin B1 
Fumonisin B1, is the most toxic and prevalent secondary metabolite produced by fungi in the 
Fusarium sp., but most commonly by Fusarium verticilliodes (Gelderblom et al. 1988). South 
Africans are continuously exposed to low doses of FB1, with a daily dietary intake of 200µg/kg 
body weight (IPCS 2001) according to the world health organisation (WHO). This mycotoxin is 
well characterised as a contaminant of maize and maize-based products both locally and worldwide 
(cited in Grenier et al. 2012). There have also been reports of FB1 found in other grains such as rice 
(Park et al. 2005), wheat and oats in Southern Brazil (Mallmann et al. 2001), including animal 
feeds. Poor storage conditions is the leading cause of contamination, where fungi favour moist, 
humid and dark conditions to grow (Hussein & Brasel 2001). This natural toxin has a wide range of 
toxic effects in both humans and animals. It has also been classified as a possible class 2B 
carcinogen by the  International Agency for Research on Cancer (IARC) (IARC 1993). 
 
2.1.1 Chemical Structure 
Fumonisins’ chemical structure was first reported by Gelderblom et al. (1988), which was followed 
by the discovery of more than 28 homologues (cited by Voss et al. 2007). The structure is based on 
a hydroxylated hydrocarbon chain, rather than a cyclic structure most commonly associated with 
mycotoxins (Heidtmann-Bemvenuti et al. 2011). Fumonisin B1 is the most common and thoroughly 
studied of the fumonisin homologues (Voss et al. 2007) and is the most prevalent mycotoxin in 
Africa due to maize being the staple diet of most rural inhabitants (Domijan & Abramov 2011). 
Fumonisin B1 is a diester of propane-1,2,3-tricarboxylic acid (TCA) and 2-amino-12,16-dimethyl-
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3,5,10,14,15-pentahydroxyeicosane, in which the carbon in position 14 (C14) and C15 hydroxyl 
groups are esterfied with a terminal carboxyl group of TCA (Figure 2.1A) (Soriano et al. 2005). The 
chemical structure of FB1 is similar to sphingoid bases: sphinganine (Sa) and sphingosine (So) 
(Figure 2.1B and C) which are important molecules in the biosynthesis of sphingolipids. The 
sphingoid bases consist of an amine and two alcohol groups attached to a 3C chain which is 
connected to a long hydrocarbon chain (Figure 2.1B and C). This structural similarity is critical for 
FB1 toxicity, where it disrupts the sphingolipid metabolism (Wang et al. 1991). The free amino 
group in FB1 (Figure 2.1A) creates an amino pentol backbone, that is important in FB1 toxic 
activity, where it competes with the sphingoid bases in the biosynthesis of sphingolipids (Soriano et 








Figure 2.1: Chemical structure of (A) Fumonisin B1 and its similarities to sphingoid bases (B) 












2.1.2 Mechanism of Toxicity 
Fumonisin B1 exerts its toxic effect through the disruption of sphingolipid metabolism (Wang et al. 
1991). The structural similarity between FB1 and the sphingoid bases: Sa and So, allow for the 
competitive inhibition of the rate limiting enzyme, ceramide synthase, in the de novo biosynthesis 
of sphingolipids (Figure 2.2) (cited in Voss et al. 2007).  
 
2.1.2.1 De novo Sphingolipid biosynthesis 
Sphingolipids play an important role in plasma membrane structure, cell growth regulation and in 
the transduction pathway, where ceramide acts as a second messenger for a range of factors such as 
TNF (Soriano et al. 2005). The de novo biosynthesis of sphingolipids (Figure 2.2) occurs at the 
cytosolic face of the ER. The first step is catalysed by serine palmitoyl-transferase, where serine 
and palmitoyl-CoA are condensed to form 3’-keto-Sa, which is then reduced to form Sa or 
dihydroSo. Sphinganine can either by phosphorylated to form Sa-1-phosphate or N-acylated to 
dihydroceramide by ceramide synthase (CS). The dihydroceramide undergoes desaturation to 
produce ceramide. Ceramide can either be transformed to form sphingomyelin or glycolipids, 
through the addition of phosphocholine or oligosaccharides, respectively. Sphingosine is generated 
through the catalytic conversion of ceramide by ceramidase. Sphingosine is phosphorylated by So 
kinase to produce So-1-phosphate. Sphingosine-1-phosphate and Sa-1-phosphate have the potential 
to produce ethanolamine phosphate and fatty aldehyde. When the last products are converted to 













Figure 2.2: Schematic summary of sphingolipid metabolism and the disruption of the de novo 
synthesis of ceramide due to the inhibition (X) of ceramide synthase by FB1 (Voss et al. 2007). 
 
2.1.2.2 Competitive Inhibition of ceramide biosynthesis 
Ceramide synthase is an important enzyme in sphingolipid metabolism; it is responsible for the 
acylation of Sa to form ceramide and the reacylation of So to ceramide. The amino-pentol backbone 
of FB1 competes for the same binding site on ceramide synthase as the sphingoid base substrates 
and FB1’s anionic TCA interferes with the binding site for the fatty acyl-CoA, therefore effectively 
inhibiting ceramide synthase (Merrill et al. 2001). The inhibition of ceramide synthase leads to a 
cascade of events; which include the inhibition of ceramide biosynthesis, increased free Sa and So, 
decreased reacylation of So derived from complex sphingolipid turnover and increased sphingoid 
base degradation of dietary sphingolipids (Riley et al. 2001). The accumulation of free Sa and few 
So and their metabolites in tissue has been correlated with apoptosis in the liver and kidneys of rats 
(reviewed by Voss et al. 2007), thus suggesting that Sa and So exert a pro-apoptotic effect as a 
mechanism of FB1 toxicity. The inhibition of ceramide formation results in fewer complex 
sphingolipids such as sphingomyelin, which is a major component of the plasma membrane. This 
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compromises the integrity of the plasma membrane thus suggesting a further mechanism of FB1 
toxicity (Nour et al. 2007).  
 
2.1.3 Toxicity 
2.1.3.1 In Animals 
Fumonisin B1 is associated with several animal diseases as a result of consumption of mouldy 
maize and feeds. It has been reported that F. verticillioides’ FB1 is the main cause of equine 
leukoencephalomalacia (Kellerman et al. 1990) and has been shown to be cardiotoxic to pigs and 
also causes porcine pulmonary oedema (Harrison et al. 1990; Voss et al. 2007). In rats, FB1 has 
been shown to be hepatotoxic and nephrotoxic (Gelderblom et al. 1991). 
 
2.1.3.2 In Humans 
In humans, it has been linked with higher incidences  of oesophageal cancers in the Transkei 
Region (Marasas et al. 1988). In populations consuming large amounts of contaminated maize, 
there has been higher incidences of neural tube defects in foetuses and cardiovascular problems 
(Gelineau-van Waes et al. 2005; Fincham et al. 1992). There is also a higher incidence in 
hepatotoxicity and nephrotoxicity observed where maize is the staple diet of the population (IPCS 
2001; cited in Domijan & Abramov 2011). 
 
2.2 Tissue Transglutaminase 
Transglutaminases (E.C 2.3.2.13) are enzymes that catalyse post-translational modifications of 
proteins. There are 9 different TGs identified within the human body all having different 
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biochemical functions (Table 2.1). Tissue transglutaminase is a unique member of this family, due 
to it also being able to act as a G-protein when bound to guanosine-5'-triphosphate (GTP). Tissue 
transglutaminase is a ubiquitous protein that is predominately found in the cytosol (80%) but is also 
localised in plasma (10-15%) and in the nuclear membrane. Tissue transglutaminase is an important 
enzyme in a number of biological processes such as cell differentiation and proliferation, 
extracellular matrix organisation, cell signalling and apoptosis (cited in Martin et al. 2012). 

















The TG2 gene is located on chromosome 20q11-12, it is 32.5kb in size and consists of 13 exons and 
12 introns (Gentile et al. 1994). Regulatory sequences are found on the 5’ terminal region of the 
TGM2 (Figure 2.3), where transcription factors bind and activate transcription of TG2 (Elli et al. 
2009). There are several transcriptional inducers of TG2 which include retinoic acid, cyclic 
adenosine monophosphate (AMP), hydrogen peroxide, vitamin D, steroid hormones, cytokines and 
growth factors including: TNFα, IL-6, transforming growth factor (TGF)-β and interferon- ƴ and β 
(cited in Elli et al. 2009). Nuclear factor kappa B has also been found to induce TG2 transcription 






Figure 2.3: Tissue transglutaminase promoter gene. Illustrating the proximal binding sites of 
transcriptional inducers of TGM2 (Ientile et al. 2007). 
 
The full length TG2 protein consists of 687 amino acids and is approximately 77kDa in size. Tissue 
transglutaminase has four distinct domains (Figure 2.4A): an N-terminal β-sandwich with 
fibronectin and integrin binding sites, a central catalytic core that contains a catalytic triad (cysteine 
277, histidine 335 and aspartic acid 358) for the acyl transfer reaction and a conserved tryptophan 
(Trp) which is vital for catalytic activity. There are also two C-terminal β-barrel domains where the 
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second domain contains a phospholipase C binding sequence (reviewed by: Fesus & Piacentini 







Figure 2.4: Structural (A) and functional (B) domains suggested for the human TG2 gene (Lesort et 
al. 2000). 
 
The catalytic core contains domains for adenosine triphosphate (ATP)/GTP and calcium binding 
sites as well as the active site which consists of the catalytic triad (Figure 2.4B). When TG2 is 
bound to guanosine diphosphate (GDP), the catalytic triad is blocked by two loops and the active 
site cysteine is hydrogen-bonded to a tyrosine residue thus rendering TG2 transamidation activity 
latent (Figure 2.5B) (Liu et al. 2002). Upon calcium binding, TG2 undergoes a conformational 
change which induces the transamidation activity of TG2 by exposing the active site. The 
conformational change occurs through an increase in the interdomain distance between the catalytic 
domain and the two C-terminal barrel domains which exposes the catalytic triad to substrates 
(Figure 2.5C) (Pinkas et al. 2007). When TG2 is bound to ATP, it does not inhibit TG2 










Figure 2.5: Structure of TG2 under normal conditions (A) TG2 bound to GTP (B) and TG2 
activated in the presence of calcium (C) (Griffin et al. 2002). The blue section indicates the catalytic 
core, green indicates the β-barrel and pink indicates the barrel domain. 
 
2.2.2 Biochemical Function 
Tissue transglutaminase is unique because it not only catalyses the post-translational modification 
of proteins but also has GTPase activity where it participates in transmembrane signalling (Figure 
2.6). Under normal physiological conditions, TG2 activity is latent due to low intracellular calcium 
concentrations (10-20nM) and high GTP concentrations (Fesus & Piacentini 2002; Kuo et al. 2011). 
Under pathophysiological conditions however, when the intracellular calcium concentration (>700-
800nM) is high; TG2 crosslinking ability is activated (Kuo et al. 2011). This binding of GTP and 
calcium is regulated in a reciprocal manner, where GTP binding inhibits calcium binding and vice 
versa (Martin et al. 2012). 
 
2.2.2.1 Post-translation modification of proteins 
This reaction occurs via a two-step mechanism: 
The transamidation activity of TG2 is activated by calcium binding resulting in the exposure of the 





cysteine residue to produce a thioacyl-enzyme intermediate and ammonia. The nucleophilic primary 
amine substrate reacts with the thioacyl-enzyme intermediate, resulting in a covalent bond between 
the amine donor and the glutaminyl acceptor. The cysteine residue within the active site is 
regenerated once the covalent bond is formed. 
When the primary amine is donated by a polyamine then a ƴ-glutamylamine bond is produced 
(Figure 2.6A1). A polyamine can also act as a N,N-bis (ƴ-L-glutamyl) polyamine bridge between 
two glutamine donors, whether on the same protein or between different proteins. If the primary 
amine is donated by the Ɛ-amino group of the lysine residue of the substrate a protease-resistant 
covalent N-ƴ-glutamyl-Ɛ-lysyl-isopeptide bond is generated (Figure 2.6A2). In the absence of a 
primary amine donor, water may act as the attacking nucleophile resulting in the deamidation of the 
donor glutamine to glutamate (Figure 2.6A3) (cited in Martin et al. 2012; Elli et al. 2009).  
Tissue transglutaminase has isopeptidase activity (Figure 2.6A4). It can also be externalised from 
the cell to the extracellular space where it promotes cell-matrix interactions, especially between 
fibronectin and integrin, and it crosslinks proteins within the extracellular matrix (Figure 2.6B5) 
(Fesus & Piacentini 2002). 
 
2.2.2.2 Guanine Triphosphatase activity 
The binding and hydrolysing of GTP by TG2, is with an affinity and catalytic rate similar to 
heterotrimetric G protein α subunits and small Ras-type G proteins. This TG2 bound to GDP 
(Figure 2.6B) couples α-adrenoreceptors, oxytocin and thromboxane receptors to phospholipase C 
thus initiating inositol phosphate production. This stimulates a transmembrane signalling cascade 

















Figure 2.6: Tissue transglutaminase’s Biochemical Activities. Catalytic calcium-dependent acyl 
transfer  (A) between: ƴ-carboxamide group of glutamine substrates and either primary amines (1) 
or the Ɛ-amine group of protein bound lysine residue to form an irreversible crosslink (2), water can 
replace the amine donor substrate which results in deamination of glutamine to glutamate (3) and 
isopeptidase activity of TG2 (4). Guanosine triphosphate-bound TG2 promotes cell-matrix 
interactions (5) and has GTPase activity where it binds and activates phospholipase C thereby 
initiating transmembrane signaling (6) pathways. Tissue transglutaminase functions within the 












2.2.3 Role in apoptosis 
Apoptosis is an important pathway that controls normal growth and tissue homeostasis. The 
induction and activation of TG2 has been linked to increased apoptosis in rat hepatocytes (Fesus et 
al. 1987);  with widespread evidence for TG2 gene up-regulation during apoptosis (cited in Griffin 
et al. 2002). An important feature of TG2 calcium-dependent crosslinking activity is the 
stabilisation of apoptotic cells prior to phagocytic clearance during the final events of apoptosis 
(Knight et al. 1991). This stabilisation is a result of detergent-insoluble protein scaffolds that form 
to prevent the release of harmful intracellular components into the extracellular space, which limits 
inflammation and auto-immune responses (Piredda et al. 1997; Fesus & Piacentini 2002).   
During increased intracellular calcium levels, TG2 is translocated into the nucleus via importin α3, 
a nuclear transporter (Peng et al. 1999). Nuclear TG2 (nTG2) regulates gene expression through 
post-translational modifications and interactions with transcription factor and related proteins such 
as Sp1 and histones. This feature of nTG2 allows it to control cell growth and apoptosis. Nuclear 
TG2 crosslinks core histone proteins: H2A, H2B, H3 and H4, which are glutamine substrates of 
nTG2 (Ballestar et al. 1996). These crosslinked histones are suggested to contribute to chromatin 
condensation which is a morphological hallmark of apoptosis (Park et al. 2010).  
A general transcription factor, Sp1 that is rich in lysine and glutamine residues is a good substrate 
for TG2 transamidation. Nuclear TG2 crosslinks Sp1 resulting in dimers and trimers of Sp1, which 
has been suggested to have higher transcription factor activation activity compared to a single Sp1 
molecule. It has also been reported however, that highly crosslinked and oligomerised Sp1 leads to 
inactivation and silencing of Sp1 transcriptional activity in hepatocytes, leading to decrease 
expression of c-Met. Increased TG2 activity therefore, leads to silencing of Sp1 and a decrease in 




2.2.4 Role in inflammation 
An increase in TG2 activity has been observed in inflammation and fibrotic conditions (Martin et al. 
2012). The inappropriate protein associations that form due to TG2 crosslinking activity could 
become cytotoxic and induce inflammatory responses (Ientile et al. 2007). A central downstream 
mediator of inflammation, NFkB is activated by TG2. The inhibitor of NFkB; inhibitor kappa B 
(IkB) is polymerised by TG2, where it crosslinks its C-terminal glutamine cluster which renders 
IkBα inactive (Figure 2.7). Upon inactivation of IkB, NFkB is activated and able to enter the 
nucleus and act as a transcription factor (Lee et al. 2004; Ientile et al. 2007). Interestingly, NFkB is 
also a transcriptional inducer of TG2, where NFkB binds the TGM2 promoter gene directly and 








Figure 2.7: Proposed mechanism of TG2 induction and activation of NFkB (p50p65 molecule) 
(Ientile et al. 2007) 
 
2.2.5 Disease associated with Tissue transglutaminase 
Tissue transglutaminase has been reported in several inflammatory, neurodegenerative and liver 
diseases such as Coeliac disease, Huntington’s Disease and Alzheimer’s Disease. Coeliac disease is 
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a malabsorption syndrome, characterised by atrophy of villi in the jejunum on exposure to dietary 
glutens. Tissue transglutaminase deamidates specific glutamines that stimulate T-cell stimulatory 
gluten peptides. This leads to an immune response that destroys jejunum epithelium. Huntington’s 
disease is characterised by progressive loss of neuronal cells due to the accumulation of 
ubiquitinated huntintin (htt) aggregates within the nucleus. There is an expansion of cytosine 
adenine guanine (CAG) trinucleotide repeats in the gene encoding for htt which results in a large 
number of contiguous glutamine residues in the htt protein. These htt aggregates, could be due to 
TG2 activity, as the expanded polyglutamine repeats are excellent glutamine donors for TG2 
(reviewed in Fesus & Piacentini 2002). 
 
2.3 Endoplasmic Reticulum Stress Pathway 
2.3.1 The Endoplasmic Reticulum 
The ER is a vast membranous organelle (Figure 2.8) (Hotamisligil 2010), that is the site of 
synthesis, folding, maturation and modification and trafficking of secreted and transmembrane 
proteins (Rutkowski & Kaufman 2004; Saito et al. 2011). The ER also acts as a major reservoir of 
intracellular calcium and therefore also plays a critical role in calcium homeostasis (Hetz 2012; 
Hotamisligil 2010). Due to this central regulatory role of the ER, it is paramount for the ER to 
possess the ability to adapt its capacity to manage metabolic, synthetic and other adverse conditions 
(Hotamisligil 2010). This adaptive capacity of the ER, is achieved by the quality control machinery 
in the ER, which operates in concurrence with the protein folding pathways (Rutkowski & Kaufman 
2004). This machinery is highly selective, so that minor perturbations in the efficiency of protein 
folding would lead to the rejection of nascent proteins as misfolded, consequently causing the 
accumulation and degradation of these misfolded proteins (Rutkowski & Kaufman 2004). The 
presence of ERAD machinery, ensures that unfolded or misfolded proteins are retrotranslated to the 
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cytosol for targeted proteasomal degradation (Pagliassotti 2012).  The increase in the accumulation 
of misfolded or UP within the ER lumen, irrespective of ERAD function, is sensed by resident 
molecules of the ER (Rutkowski & Kaufman 2004) and initiates the adaptive response known as the 







Figure 2.8: The Endoplasmic Reticulum (ER). Diagram of Rough ER with ribosomes and smooth 
ER without ribosomes (Above). Micrograph of both smooth and rough ER within the cell (Below) 
(Campbell et al. 2007). 
 
2.3.2 Unfolded Protein Response Signaling 
The UPR is initiated within the ER when protein folding becomes compromised. This could be a 
result of mutations in genes coding for transmembrane and secretory proteins, pathogen infections 
or metabolic conditions such as ischemia (Rutkowski & Kaufman 2004). Three ER membrane-
bound proteins: IRE1α, PERK and ATF6 act as UPR sensors that monitor the ER lumen for UP and 
transduce signals to the cytosol and nucleus. In stress free conditions, luminal protein chaperone 
binding immunoglobulin protein (BiP) binds to the intraluminal domain of these UPR sensors, 
rendering them inactive (Bertolotti et al. 2000). The accumulation of UP and increased protein 
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cargo within the ER, leads to the dissociation of BiP from the UPR sensors, and sequester on UP 
due to its higher affinity for UP (Bertolotti et al. 2000). The dissociation of BiP from IRE1α (Figure 
2.9A) and PERK (Figure 2.9C) causes the oligomerisation, auto-phosphorylation and activation of 
these sensors and downstream signalling pathways (Hotamisligil 2010; Pagliassotti 2012). Whilst 
the dissociation of BiP from ATF6 allows the translocation of ATF6 to the Golgi apparatus, where 
it is processed by serine protease 1 (S1P) and metalloprotease site-2 protease (S2P) to yield an 
active transcription factor which enters the nucleus (Figure 2.9B) (Shen et al. 2002). The UP 
sequestered on BiP are translocated to the cytosol for proteasomal degradation by ERAD (Kaufman 
2004). These three arms of UPR mitigate ER stress by suppressing protein synthesis, facilitate 
protein degradation and increase protein folding capacity of ER by increasing the production of 








Figure 2.9: The Unfolded Protein Response (UPR). The UPR stress sensors are activated when 
there is an accumulation of misfolded proteins within the ER lumen. This causes BiP dissociation 
from the UPR sensors and sequester on unfolded proteins. The unfolded proteins undergo 
proteasomal degradation. The active UPR sensors initiate downstream signalling mechanisms to 





transcription factor 6 (ATF6) pathway and (C) protein kinase RNA-like endoplasmic reticulum 
kinase (PERK) pathway (Kaufman 2004). 
 
2.3.3 Protein kinase ribonucleic-like endoplasmic reticulum kinase Attenuation of Protein         
        Translation 
The first step in protein synthesis is the transcription of the genetic code into mRNA. The mRNA is 
then translated into polypeptides or proteins. The translation initiation step is controlled by eIFs. 
The binding of the 40S ribosomal RNA (rRNA) and transfer RNA (tRNA), is dependent on group 2 
eIF proteins (eIF2α and eIF2β), to form the 43S pre-initiation complex. After the 43S pre-initiation 
complex is assembled it binds to mRNA to generate the 48S pre-initiation complex. This step is 
regulated by eIF group 3 and 4F. During ER stress, these eIFs are targeted and inactivated which 
results in the attenuation of protein translation (reviewed in Lasfargues et al. 2013). 
The reversible, transient attenuation of translation initiation is the immediate response to ER stress 
which reduces the demand on protein folding machinery (Kaufman 2004; Malhotra & Kaufman 
2007). This inhibition of protein translation is a downstream effect of PERK activation. The N-
terminal domain of PERK, an ER type 1 transmembrane protein kinase, is exposed to the ER lumen 
and is sensitive to ER stress signals (Ron 2002). Its C-terminal cytoplasmic serine/threonine kinase 
domain directly phosphorylates eIF2α (Rutkowski & Kaufman 2004). 
The heterotrimetric complex, eIF2, is composed of eIF2α, β and ƴ. In order for tRNA to interact 
with the eIF2 complex, the eIF2ƴ subunit needs to be bound to a GTP molecule. This interaction is 
controlled by eIF2β, as it possesses a guanine nucleotide exchange factor (GEF) where it converts 
GDP to GTP (Lasfargues et al. 2013). This ternary complex of eIF2-GTP-tRNA
Met
 delivers the 
initiator methionyl tRNA to the 40S ribosomal subunit which is essential for adenine uracil guanine 
(AUG) start codon selection during translation (Kaufman 2004). During ER stress however, PERK 
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activation leads to the phosphorylation of serine 51 on eIF2α which causes GEF to have a higher 
affinity for GDP and is sequestered by the eIF2ƴ subunit. This inhibition of tRNA and eIF2 
complex interaction due to eIF2α phosphorylation, prevents the assembly of the 43S pre-initiation 
complex which leads to the attenuation of protein synthesis (Figure 2.10) (Kaufman 2004; 






Figure 2.10: The regulation of eIF2 activity. The association between eIF2ƴ subunit with GTP 
occurs as a result of guanine nucleotide exchange activity of eIF2β. This results in the formation of 
the ternary eIF2.GTP.Met.tRNA initiation complex. The phosphorylation of eIF2α by PERK inhibit 
eIF2β exchange activity which inhibits the formation of the initiation complex (Lasfargues et al. 
2013). 
 
Stressed cells require the activity of pro-survival and pro-apoptotic proteins and therefore require 
protein synthesis of specific proteins. Eukaryotic initiating factor 2α phosphorylation, can therefore 
paradoxically stimulate the selective translation of specific mRNAs (Kaufman 2004). The synthesis 
of these proteins is permitted despite general protein synthesis attenuation, due to their mRNAs 
containing specific cis-acting elements that allow for ribosomal recruitment (Lasfargues et al. 
2013). The activation of PERK leads to the phosphorylation of eIF2α which stimulates the 
translation of ATF4 mRNA. In non-stressed cells, ATF4 mRNA translation is silenced due to the 
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presence of 2 short upstream open reading frames (µORF), located within the 5’ untranslated region 
(UTR). After ribosomes translate the first µORF, they can efficiently re-initiate at the second µORF 
which prevents translational initiation at the downstream ATF4 start codon therefore silencing the 
ATF4 mRNA. Upon ER stress, eIF2 becomes phosphorylated which impairs the initiation at the 
second µORF due to decreased ternary complex activity. The second µORF is therefore bypassed 
and the ribosomes are able to scan the downstream ATF4 start codon, allowing for the translation of 
ATF4 mRNA (Lasfargues et al. 2013). Activating transcription factor 4 controls selective pro-
survival genes related to amino acid metabolism, redox balance, protein folding and autophagy as 
well as several microRNAs that contribute to the inhibition of protein synthesis (Hetz 2012). 
The transcription factor CHOP is also translated paradoxically during translation attenuation 
activated by PERK. The phosphorylation of eIF2α allows the ribosome to bypass an inhibitory 
µORF which allows the mRNA translation of CHOP (Lasfargues et al. 2013). This transcription 
factor is upregulated by ATF4 and is involved in ER stress mediated apoptosis (Fawcett et al. 
1999).   
 
2.3.4 Protein kinase ribonucleic-like endoplasmic reticulum kinase Activation of Nuclear factor  
         kappa B 
It has been reported that ER stress activates NFkB (cited in Tam et al. 2012). Nuclear factor kappa 
B is found within the cytosol bound to IkB which renders NFkB inactive. A protein IkB kinase 
(IKK) is composed of IKKα, β and ƴ subunits. The IKKβ subunit phosphorylates IkBα serines at 
position 32 and 36 which then undergoes proteasome-mediated degradation. This phosphorylation 
and degradation of IkBα, allows the release and activation of NFkB. The active NFkB translocates 
to the nucleus and binds to its consensus sequence, leading to the transcriptional activation of target 
genes (DiDonato et al. 1996). The activation of NFkB has been linked to PERK-mediated eIF2α 
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phosphorylation; where the attenuation of translation leads to a rapid decrease in IkBα due to its 
relatively short-half life and the inhibition of translation. This consequently, leads to an 
accumulation of free and active NFkB present within the cytosol. It was shown that the extent of 
translational attenuation is directly proportional to the level of active NFkB (cited in Tam et al. 
2012). Nuclear factor kappa B is an important regulator of inflammatory mediators such as TNF-α 
and IL-6 (Li et al. 2005). 
 
2.3.5 Endoplasmic Reticulum Stress Feedback Mechanisms 
The UPR requires a feedback mechanism that prevents a hyper-activated response or prematurely 
turned off response. This negative feedback loop is done through the repression of the PERK 
pathway, mediated by p58
IPK
 a co-chaperone and growth arrest and deoxyribonucleic acid (DNA) 
damage-inducible protein (GADD34). The activation of the PERK pathway leads to the 
transcription of ATF4 which up-regulates GADD34 expression. This gene associates with protein 
phosphatase1 (PP1) which contains an ER localised motif. This motif dephosphorylates eIF2α 
which leads to increased protein synthesis and restoration of ER folding capacity. The p58
IPK
 gene 
down-regulates and dephosphorylates PERK which leads to the termination of the UPR when the 
ER folding capacity returns to normal and ER stress is overcome (Yan et al. 2002; Rutkowski & 
Kaufman 2004).  
 
2.3.6 Endoplasmic Reticulum Stress Induced Apoptosis 
In circumstances where the translational adaptive responses are insufficient and fail to resolve 
protein folding defects to restore the protein folding capacity of the ER due to prolonged or severe 
stress; the apoptotic pathway is activated (Lasfargues et al. 2013; Malhotra & Kaufman 2007). The 
initiation of apoptosis occurs via two signalling pathways: the intrinsic mitochondrial-dependent 
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pathway and the extrinsic mitochondrial-independent pathway. The extrinsic pathway, involves Fas 
(member of TNF family) death receptor-induced activation of initiator caspase 8 which activates 
downstream effector caspase 3. The intrinsic pathway, involves mitochondrial induction by B-cell 
lymphoma 2 (Bcl-2) family of proteins, such as Bax, to release cytochrome c into the cytosol. The 
cytochrome c then binds apoptotic protease activating factor 1 (Apaf-1) resulting in initiator caspase 
9 activation which forms an apoptosome that activates caspase 3. The activated effector caspases 
induce the cleavage of cellular components, especially the cytoskeleton causing apoptosis (Ghobrial 
et al. 2009; Rutkowski & Kaufman 2004). 
Apoptosis induced by ER stress is described more often as an intrinsic pathway however, it has 
elements of both extrinsic and intrinsic pathways. Apoptosis is induced by the following signals 
(Figure 2.11): 
Caspase 12 localised within the ER membrane is dissociated from TNF receptor-associated factor 
(TRAF2) which allows its dimerization and activation which leads to the activation of caspase 9 
independent of cytochrome c and Apaf-1. The active caspase 9 then activates downstream effectors 
of apoptosis (Rutkowski & Kaufman 2004). 
The apoptosis signal-regulating kinase 1 (ASK1)/ c-jun N-terminal kinase (JNK) pathway is 
activated by IRE1α. Endoplasmic reticulum stress causes the interaction between IRE1 and TRAF2, 
which results in the activation of ASK1 and JNK leading to the initiation of the proapoptotic 
phosphorylation cascade (Rutkowski & Kaufman 2004). 
The calcium concentration regulation within the ER might also act as a trigger for apoptosis. 
Endoplasmic reticulum stress triggers conformational changes and oligomerisation of Bcl-2 
homology (BH) 3-only proteins such as Bax and Bak, at the ER membrane. The ER localised Bak 
causes the depletion of calcium within the ER which activates caspase 12. The rapid release of 
calcium from the ER into the cytosol, leads to calcium uptake within the mitochondria which causes 
26 
 
the collapse of mitochondrial inner-membrane potential most commonly associated with apoptosis 
(Rutkowski & Kaufman 2004).  
The transcriptional suppression of anti-apoptotic Bcl-2 protein by CHOP induces apoptosis. The 
pro-apoptotic transcription factor, CHOP is induced and activated by the PERK/eIF2α-dependent 
ER stress pathway (Rutkowski & Kaufman 2004). The transcription factor, CHOP is known to 
activate the transcription of several genes that have the potential to initiate apoptosis; these include 
GADD34 and death receptor (DR) 5. The gene GADD34 encodes for protein phosphatase 2C 
subunits that dephosphorylates eIF2α and promotes protein synthesis. Increased protein synthesis 
during ER stress, leads to the chronic activation of the UPR therefore inducing apoptosis as the ER 
cannot resolve proper protein folding capacity. The DR5 gene encodes death receptors on the cell 








Figure 2.11: The ER stress induced Apoptosis via: PERK/eIF2α mediated CHOP transcription, 
Bak/Bax regulation of calcium release from ER, IRE1 mediated activation of ASK1 and JNK and 




3 MATERIALS AND METHODS 
3.1 Cell Culture 
HepG2 cells are a human liver hepatocellular carcinoma cell line and were purchased from 
Highveld Biological Association (Johannesburg, RSA). Fumonisin B1 is highly cytotoxic especially 
to the liver, where it has been reported in studies that FB1 causes hepatocarcinogenity in mice and 
liver injury (He et al. 2005). The liver, as a result of its regenerative properties and the first site of 
detoxification of harmful substances including FB1, is an important organ within the body. It is 
therefore, important to determine the effects of FB1 on the liver and to specifically look at 
mechanisms by which liver damage occurs. 
HepG2 cells were cultured in Eagle's minimal essential medium buffer (Lonza) supplemented with 
10% Foetal Calf serum (GIP Co), 1% penicillin/streptomycin (GIP Co), 1% Gentamycin (Sigma, 
lot 95K2411) and 1% L-glutamate (GIP Co). 
HepG2 cells were first reconstituted; vials containing 1x10
6
 cells/ml were removed from liquid 
nitrogen and thawed at 37°C. Once the cells were thawed, they were placed into a medium flask and 
10ml cell medium was added to the flask and incubated for 24hours to allow the cells to attach to 
the flask. After 24hours, the cell medium was removed, the cells washed with 5ml 0.1M PBS 
(pH7.4) twice and 10ml of fresh cell media was added to the flask. The flask was incubated at 37°C 
for 3days to allow the cells to increase in number. When the flask was 90% confluent, the flask was 
trypsinised and half the cells were cryopreserved and the other half used to continue making a cell 
stock. To trypsinise cells, the cell medium was removed from the confluent flask, the cells washed 
with 5ml 0.1M PBS (pH7.4) twice to remove media, as the foetal calf serum deactivates the trypsin. 
To the flask, 1ml of Trypsin-Versene (EDTA) (GIP Co) was added and the flask incubated for 
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5minutes at 37°C, to allow the Trypsin to break the adherent proteins between cells and the flask. 
After the proteolytic activity of the Trypsin the cells appeared round. The trypsin was removed from 
the flask and 2ml of cell media was added to the flask. The flask was then gently agitated 
repeatedly, against the palm of the hand, to detach the cells from the flask surface. The cells were 
then collected within a 15ml sterlin tube and the cells were counted. To count the number of cells 
within the flask after trypsinisation, the Trypan Blue method was used. In an eppendorf 150µl of 
cell media, 50µl 3.4% Trypan blue and 50µl cell suspension was added to make the Trypan blue 
solution. A cover slip was placed over the hemocytometer chamber and 10µl of the above Trypan 
blue solution was added to both chambers of the hemacytometer, using capillary action. The 
hemocytometer was observed under a microscope with a 10x ocular and 10x objective and the cells 
counted within each of the 5 squares (Figure 3.1A). The hemocytometer is divided into nine 1mm 
squares and the cover glass is supported 0.1mm from the surface of the chamber which allows for a 




 is approximately equivalent to 1ml, the 
cell concentration per ml will be the average count per square times 10 000. As the cells were 
diluted, the dilution factor must also be taken into account therefore, to determine the number of 
cells per ml the average count per square was multiplied by 1x10
4
 and multiplied by the dilution 






Figure 3.1: (A) Image of the hemocytometer and the 5 squares the cells are counted within (Harisha 





Once the cells were counted, half the cells were cryopreserved and the other half were placed in a 
flask with 10ml cell media and incubated at 37°C to further replicate and then used for experiments 
once the cells were confluent. The cells undergoing cryopreservation, were placed in cell media 
containing 20% foetal calf serum. Equal volume cell suspension and dimethyl sulfoxide (DMSO) 
(1ml of each) were added to the cryopreservation vial, mixed well and placed within an isopropanol 
tube overnight which allowed the cells to freeze at a rate of 0.5-2°C per minute throughout the 
range of 4 and -30°C. After the incubation period, the vials were removed from the isopropanol 
tube and stored at -80°C. 
 
3.2 Fumonisin B1 Preparation 
Fumonisin B1 (FB1) was obtained from the PROMEC Unit, Batch A/11 at a mass of 5.01mg. A 
stock of 6.93mM (5mg/ml) was prepared by dissolving the 5.01mg FB1 in 1ml 0.1M PBS (pH7.4). 
From this stock a 1mM working concentration in 1ml was prepared (use 144µl 6.93mM stock) and 
used for treatments. The cell viability assay was performed to determine the treatment 
concentrations (Appendix A; figure A1 and A2). 
 
3.3 Protein Expression Analysis 
To determine the protein expression in HepG2 cells after treatment with FB1, the sodium dodecyl 
sulfate (SDS) polyacrylamide gel electrophoresis (PAGE) and western blotting was performed.  The 
SDS-PAGE is a relatively simple technique used to separate proteins based on their molecular size 
which involves the migration and sieving of protein complexes through the polyacrylamide gel 
matrix. This technique has a higher resolution compared to other separation methods, due to the 
combination of its sieving and SDS properties within the gel matrix and the gels relative pore sizes. 
Initially the proteins react with SDS, an anionic detergent, which denatures the protein therefore 
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destroying its tertiary structure. The SDS binds to both the hydrophilic and hydrophobic areas, 
within the polypeptide chain for each protein subunit therefore, producing negatively charged rod 
shaped molecules that have negatively charged sulfonate ions attached through the polypeptide 
surface. The intrinsic charge of the SDS-protein complex as a result of the individual amino acids is 
buried therefore, this complex has a net negative charge (Banga 1998; Pagano 1999). 
After the formation of these SDS-protein complexes, the proteins need to be separated according to 
the different polypeptide components, i.e. molecular size. These complexes are separated by 
applying an electric current through a polyacrylamide gel which allows for SDS-protein complex 
migration. A synthetic polymer, polyacrylamide, is formed from the catalytic polymerisation of bi-
functional cross-linking agents with acrylamide monomers. This polyacrylamide polymer consists 
of a three-dimensional network of pores, whose size is determined by the concentration ratio of 
acrylamide monomer and crosslinking agents. The molecular size of the pores within the 
polyacrylamide gel is therefore, comparable to protein molecular size. During electrophoresis, the 
application of an electrical current allows for the migration of the SDS-protein complexes through 
the polyacrylamide matrix towards the anode, thus allowing the separation of these protein 
complexes according to size. The proteins are sieved though the gel pores, so that the large proteins 
migrate at a slower rate, compared to smaller proteins that migrate at a faster rate through the gel 
matrix (Banga 1998; Pagano 1999). 
The concentration of acrylamide within the gel is important for the good separation of proteins. 
Usually proteins needed to be separated fall between the molecular weights 10-200kDa therefore an 
8-12% acrylamide gel concentration is sufficient for protein separation. The resolution of protein 
separation is increased by the incorporation of a concentration gradient of acrylamide within the 
gel. A gel with a single concentration of acrylamide however, is sufficient for separation of 
proteins. The presence of a 5-15% acrylamide concentration gradient within the gel, results in the 
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gradual reduction of pore size which leads to the gel having a greater sieving effect during 
electrophoresis which forms sharper protein bands (Banga 1998; Pagano 1999) . 
Western Blotting involves the transfer of the proteins from the SDS-polyacrylamide gel onto a 
nitrocellulose membrane, as a result of an electrical current passing through the membrane and gel. 
The membrane that has been blotted with the proteins is an exact replica of the SDS-polyacrylamide 
gel. Following this transfer, the membrane is exposed to various antibody probes to characterise 
desired proteins as a result of specific treatments (Kurien & Scofield 2006). 
 
3.3.1 Protein Isolation: 
3.3.1.1 Sample preparation for each isolation method:  
Eight small flasks were seeded with 5x10
4
 HepG2 cells/ml each and incubated at 37°C for 48hours, 
until the cells were 95% confluent. The flasks were then treated with a negative control, 10µM, 
50µM and 100µM FB1 (in duplicate) in CCM. The one set of flasks were incubated for 24hours and 
the other set for 72hours, both at 37°C. After the relevant time intervals, each flask underwent 
protein isolation.  
 
3.3.1.2 Crude Protein Extract:  
To obtain crude protein extract, each flask underwent the following procedure: The CCM was 
removed and the flask washed three times with 0.1M PBS (pH7.4). The cells were then 
homogenised using Cytobuster [500µl/flask (Novagen: #71009); containing protease inhibitor 
Cocktail (III) (Roche: #04693124001)] and the cell monolayer was removed using a cell scraper; 
whilst on ice. The sample was collected, stored in an eppendorf and incubated on ice for 10minutes. 
The samples where then centrifuged at 10 000 x g for 5minutes at 4°C, the supernatant containing 
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proteins was then standardised using the bicinchoninic acid (BCA) assay below. The protein 
homogenate was kept on ice at all times. 
 
3.3.1.3 Subcellular Fractionation was preformed according to the abcam® protocol: 
The CCM was removed and the flask washed three times with 0.1M PBS (pH7.4). The cells were 
then homogenised on ice using subcellular fractionation buffer (250mM sucrose, 20mM HEPES 
(pH 7.4), 10mM KCl, 1.5mM MgCl2, 1mM Ethylenediaminetetraacetic acid (EDTA); in 10ml 
buffer add 1mM dithiothreitol (DTT), Pl Cocktail (lll) (Roche: #04693124001)). The cell 
monolayer was removed using a cell scraper and placed in an eppendorf. The lysate was then 
passed through a 25Ga needle ten times, using a 1ml syringe and left on ice for 20minutes. 
Following incubation, the lysate was centrifuged at 720 x g for 5minutes to separate out the nuclear 
pellet. The supernatant was removed and placed in a fresh labelled eppendorf tube and centrifuged 
at 10 000 x g for 10minutes. The supernatant was removed again and placed in a fresh eppendorf; 
this was the cytosolic fraction. The nuclear pellet (from the first centrifugation) was washed once 
through the addition of fractionation buffer and passed through a 25Ga needle ten times and 
centrifuged again for 10minutes at 720 x g. The buffer was then removed and the pellet re-
suspended in nuclear buffer. Sample buffer (1:1) was added to the re-suspended nuclear fraction 
and the cytosolic fraction heated for 5minutes at 100°C and then stored at -20°C until use in SDS-
PAGE and western blotting. 
 
3.3.2 The Bicinchoninic acid Assay 
The BCA assay is based on the biuret reaction where cupric ions (Cu
2+
) from copper sulfate is 
oxidised to cuprous ions (Cu
+
) in the presence of peptide bonds. The Cu
+
 then reacts with 2BCA to 
form a stable BCA-Cu
+
 complex, which changes the colour of the reaction to purple detected at 
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562nm (Figure 3.2). This reaction occurs under alkaline conditions. In the BCA assay the Cu
2+
 ions 
are reduced by cysteine, tyrosine, cystine, tryptophan and the peptide bond to form cuprous ions 




Figure 3.2: The BCA assay reaction where the copper ions bind to proteins changing the reaction 
colour to purple with a wavelength of 562nm (prepared by author). 
 
The BCA assay is used to quantify and standardise proteins after protein isolation. A 1mg/ml stock 
of bovine serum albumin (BSA) was serially diluted to 0mg/ml, 0.2mg/ml, 0.4mg/ml, 0.6mg/ml and 
0.8mg/ml. To a 96-well plate, 25µl of each sample and the relevant standards (BSA: 0, 0.2, 0.4, 0.6, 
0.8, 1mg/ml) where added to appropriately labelled wells. To each well, 200µl BCA working 
solution (4µl 4% CuSO4 and 198µl BCA) was added. The 96-well plate was then incubated at 37°C 
for 30minutes. Following incubation, the plate was read at 562nm using a spectrometer. The 
absorbance values of the BSA standards were then used to construct a standard curve which was 
used to calculate the protein concentrations of each sample (Appendix B; figures B1 and B2). The 
samples were then standardised, using Cytobuster, to the lowest protein concentration in the sample. 
The crude protein samples from above were standardised to 1mg/ml (Appendix B; table B1). The 
subcellular fractionation protein isolates were not standardised. 
 
After standardisation and under the laminar flow hood, sample buffer (dH20, 0.5M 
Tris(hydroxymethyl)aminomethane (Tris)-HCl (pH 6.8), glycerol, 10% SDS, β-mercaptoethanol, 
Protein 
(Cysteine, cystine, 














1% bromophenol blue) was prepared, where the β-mercaptoethanol was added to the sample buffer 
at a 1:19 ratio before use. The 1x sample buffer was then added to each sample (50µl:50µl) and 
boiled for 5minutes at 100°C, in order to activate the β-mercaptoethanol and SDS to allow for 
reduction and unfolding of proteins. The samples where then stored at -20°C until use in SDS-
PAGE and western Blotting. 
 
3.3.3 Sodium Dodecyl Sulfate – Polyacrylamide Gel Electrophoresis 
The Bio Rad mini-PROTEAN 3 SDS-PAGE apparatus was assembled and the samples were run on 
a SDS-polyacrylamide gel, containing a 7.5% resolving gel (deionised water, 1.5M Tris (pH 8.8), 
10% SDS, 25% acrylamide, 10% ammonium persulfate (APS) and 0.05% 
tetramethylethylenediamine (TEMED)) and 4% stacking gel (deionised water, 0.5M Tris (pH 6.8), 
10% SDS, 10% acrylamide, 10% APS and 0.1% TEMED). A molecular weight marker, precision 
plus protein standard (Bio-Rad: #161-0373), was run alongside the samples. After sample loading, 
the gels were electrophoresed in 1L running buffer (30.3g Tris, 144g Glycine, 10g SDS and 
deionised water) for 1hour at 150V using the Bio-Rad compact power supplier and apparatus; 
whilst on ice. The run was monitored until the tracker dye reached the bottom of the gel. The gels 
then underwent western blotting. 
 
3.3.4 Western Blotting 
For western blotting, the electrophoresed gels and fibre pads were placed in transfer buffer to 
equilibrate (25mM Tris, 191.8mM glycine and 20% methanol). The gel sandwich was assembled: 
fibre pad, nitrocellulose membrane, gel and fibre pad within the Bio-Rad cassette (Figure 3.3) 
which was placed within the Bio-Rad semi-dry Western Blot machine and run for 45minutes at 
25V. After the transfer, the membranes were blocked for 1hour at 25°C, with 5% non-fat milk 
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protein in Tris-Buffered Saline with Tween 20 (TTBS). After blocking, the primary antibody      
(Table 3.1) was added overnight at 4°C. The membranes were then washed three times for 
15minutes with TTBS followed by incubation with secondary antibody (Table 3.1) for 2hours at 
25°C. After 2hours, the membranes underwent three 15 minute washes. The horseradish peroxidase 
(HRP) component of the secondary antibody was exposed for 90 seconds to enhanced Kirkegaard 
and Perry Laboratories LumiGlo® (Lot#: 111142) chemiluminescence substrate (equal parts 








Figure 3.3: Method for assembling the gel sandwich within the Bio-Rad cassette (Bio-Rad Trans 
Blot Turbo Blotting System Instruction manual). 
The membrane was viewed after chemiluminescence exposure and the image captured using the 
GelDoc XRS apparatus (Bio-Rad). 
The membranes were stripped and re-probed with β-actin, to ensure equal loading of proteins: this 
was done by adding hydrogen peroxide and TTBS (1:1 ratio) to the membranes for 30minutes at 
37°C, followed by a wash with TTBS, blocking step and then the steps as described above. The 
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western blots were analysed with Image J software and Microsoft Excel and the bands were 
normalised against β-actin. 
Table 3.1: Western Blotting Primary and Secondary Antibodies used to probe for protein 
expression; diluted in 5% non-fat milk protein in TTBS * except p-eIF2α which was diluted in 5% 
BSA in TTBS. 
Protein Primary Antibody Secondary Antibody 
TG2 
Rabbit mAb anti-TG2 
(Sigma: Lot310350) 
1:1000 
Goat anti-rabbit IgG- HRP 




Rabbit mAb anti-p-NFkB 
p65 (Ser538) (Cell 
Signaling: #3031) 
1:1000 
Goat anti-rabbit IgG- HRP 




Rabbit mAb anti-PERK 
(Cell Signaling: #5683) 
1:250 
Goat anti-rabbit IgG- HRP 




Rabbit mAb anti-p eIF2α 
(Ser51) 
(Cell Signaling: #3597) 
1:1000* 
Goat anti-rabbit IgG- HRP 




Mouse mAb anti- β actin 
peroxidase (Sigma-
Aldrich: #A3854) 
1:5000   
 
3.4 Tissue Transglutaminase Activity Assay 
The TG2 activity in HepG2 cell homogenates was measured through the incorporation of biotin-x-
cadaverine (BTC) into fibronectin. In the presence of excess calcium (above 0.5mM), TG2 
undergoes a conformational change which exposes its active site rendering the enzyme active. The 
enzyme catalyses an acyl transfer reaction; where fibronectin acts as the acyl donor and BTC acts as 
the acyl acceptor. This reaction results in the insertion of an isopeptide bond between the two 
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proteins resulting in a proteinase resistant covalent N-ƴ-glutamyl-Ɛ-lysyl-isopeptide bond or 
crosslink (Figure 3.4). The crosslink produces a higher molecular mass protein aggregate (Griffin et 
al. 2002). A 3,3’,5,5’ – Tetramethylbenzidine (TMB) tablet (Sigma-Aldrich: # T5525) was used as 
a chromogenic substrate that reacts with the extravidin peroxidase conjugates to produce a blue 
soluble end product that is detectable spectrophotometrically at 370 or 655nm. The reaction is 






Figure 3.4: Tissue transglutaminase transamidation reaction. Tissue transglutaminase catalyses an 
acyl-transfer between an acyl donor and acyl acceptor with the insertion of an isopeptide bond to 
generate a proteinase-resistant covalent N-ƴ-glutamyl-Ɛ-lysyl-isopeptide bond (Lesort et al. 2000). 
 
HepG2 cells seeded at a density of 1x10
5 
cells/ml in a 6-well plate, were treated with a negative 
control and 50µM FB1 for 24hours at 37°C. The negative control and 50µl FB1 treatments were 
only used because this experiment was being optimised therefore, to prevent wastage of FB1 
reagent. This experiment also never worked and instead was adapted in section 3.4.1. After 
incubation, the cells were rinsed with 0.1M PBS (pH7.4) twice and 200µl homogenising buffer 
(0.32M sucrose, 5mM Tris-HCl (pH 7.4), 2mM EDTA, broad range of protease inhibitor cocktail 
(Roche: #04693124001)) was added to each well. The cell monolayer was removed, using a cell 
scraper and passed through a thin gauge needle ten times to lyse the cells; whilst on ice. The 
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homogenate was then standardised, using the BCA protein assay, to protein levels of 1mg/ml BSA. 
The human plasma fibronectin (5µg/ml; Sigma- Aldrich: #F085) pre-coated 96-well plate 
(50µl/well) was blocked for 1hour at 37°C, after which it was rinsed twice with 50mM Tris-HCl 
(pH 7.4) and then incubated with the reaction mix (100µl/well) for 1 hour at 37°C (Table 3.2). The 
BTC substrate (Sigma-Aldrich: #B7306) was added last to the 1ml total reaction mix. After 
incubation, the wells were rinsed with 50mM Tris-HCl (pH 7.4) containing 5mM EDTA to stop the 
enzyme reaction (100µl/well) and then blocked with 3% BSA in 50mM Tris-HCl (pH 7.4) for 
30minutes at 37°C (100µl/well). The wells were then incubated with 100µl/well extravidin 
peroxidase conjugate (1:5000 in 3% BSA in 50mM Tris-HCl, pH 7.4; Sigma-Aldrich: #E2886)) at 
37°C for 2hours. After incubation, the wells were rinsed with 50mM Tris-HCl (pH 7.4) twice and 
then equilibrated with phosphate citrate buffer (pH 5.0) for 5minutes at 25°C (100µl/well). The 
colour development was timed for each well (between 1-5minute intervals to achieve a blue colour). 
A tablet of TMB was dissolved in 0.05 M phosphate citrate buffer (pH 5.0) containing 4µl 0.014% 
urea-hydrogen peroxide and added at 100µl/well. After the blue colour was detected the reaction 
was stopped, using 2.5M H2SO4. The plate was then analysed colorimetrically in a SpectrFluor 
ELISA plate reader at 450nm. 
Table 3.2: Reaction Mix for Colorimetric TG2 Activity Assay (Purified guinea pig liver (gpl) TG2 
(Sigma-Aldrich: #T5398):  0, 10 and 20ng to set up a standard curve, this was repeated with 






Positive Reaction Mix Negative Reaction Mix 
10mM CaCl2 10mM EDTA 
10mM DTT 10mM BTC 
0.125mM BTC  
Cell homogenate/ gpl TG2  
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The purified gpl TG2 (1mg/ml) was used to set up the standard curve (Appendix C; figure C1) 
because it was of known concentration therefore, can be used to determine the concentration of TG2 
in the cell homogenates. The gpl TG2 was used as it has a molecular weight of 75kDa whilst human 
TG2 has a molecular weight of about 80kDa; therefore would have similar absorbance values. A 
FB1 inhibition curve was also down to determine whether FB1 could act as a possible substrate for 
TG2 (Appendix C; figure C2) 
 
3.4.1 Tissue transglutaminase Activity Assay (Sodium Dodecyl Sulfate – Polyacrylamide Gel  
         Electrophoresis Adaptation) 
A SDS-PAGE/western blot was done to verify TG2 enzyme activity, which was adapted from the 
colorimetric TG2 assay principle described above (Jones et al. 1997). The TG2 activity, whether 
from gpl TG2 (Sigma-Aldrich: #T5398) or HepG2 homogenates, is tested here through the 
incorporation of FB1 into fibronectin. In this assay, the reaction mix is done in 1.5ml eppendorfs 
and heated in a waterbath at 37°C for a specific reaction time period.  The samples were 
electrophoresed, using SDS-PAGE and stained with Coomassie Blue to verify equal protein loading 
of the purified human fibronectin. A duplicate SDS-PAGE gel was then processed for western blot 
transfer to detect specific proteins (FB1 and TG2). 
 
3.4.1.1 Incorporation of Fumonisin B1 into fibronectin:   
Sample Preparation: The TG2 crosslinking of FB1 into fibronectin was carried out in an eppendorf 
containing the reaction mix (Table 3.3). The concentrations of FB1 used show a negative control, a 
treatment of 100µM and 1000µM. The 1000µM FB1 treatment was done to compensate for the 
concentration of fibronectin used. In the colorimetric assay, 5µg/ml of fibronectin was used 
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however, within the adapted TG2 activity 0.5µg/ml of fibronectin was used due to dilution within 
the reaction mix. Therefore, 10 times more FB1 would need to be used to ensure the reaction 
between fibronectin and FB1 occurred, as seen in the colorimetric assay. In this reaction mix 
therefore, 1000µM FB1 and 0.5µg/ml of fibronectin is used instead of 100µM FB1 and 5µg/ml of 
fibronectin as seen in the colorimetric assay. The gpl TG2 reaction mix was incubated at 37°C for 
15minutes or 1hour, while the HepG2 homogenate reaction was incubated at 37°C for 1hour. The 
HepG2 homogenate reaction was incubated for an hour only, as it was the optimal time for the 
reaction to occur. The reactions were stopped by adding 10µl 5mM EDTA/Tris (pH 8.0). Sample 
buffer (1X) was added to each reaction mix, heated for 5minutes at 90°C then stored at -20°C until 
needed for SDS-PAGE and western blot.  
Table 3.3: Positive and negative reaction mix for the incorporation of FB1 into fibronectin; 
incubated in a waterbath at 37°C for reaction times of 15minutes and 1hour. 
 
The SDS-PAGE and western blots were carried as previously described (Section 3.3.3 and 3.3.4). 
The antibodies used and probed for are listed in table 3.4 below: 
 
Positive Reaction Mix Negative Reaction Mix 
5µl Fibronectin (5µg/ml) 5µl Fibronectin (5µg/ml) 
5µl gpl TG2 (100ng/ml) 
or 
5µl HepG2 Cell homogenate 
- 
10mM CaCl2 20mM EDTA 
10mM DTT - 
FB1 (0, 100, 1000µM) FB1 (0, 100, 1000µM) 
50mM Tris-HCl (pH 7.4) (top up to 50µl) 50mM Tris-HCl (pH 7.4) (top up to 50µl) 
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Table 3.4: Western Blotting Primary and Secondary Antibodies used to probe for TG2 activity; 
diluted in 5% non-fat milk protein in TTBS. 
Protein Primary Antibody Secondary Antibody 
FB1 
Mouse mAb anti-FB1 
(Abcam: #ab42124) 
1:1000 





Indirect immunocytochemistry (Figure 3.5) is used to detect and localise any constituent or 
inclusion of a biological system in which an antibody can be raised and marked by a visible label. 
The indirect method has higher sensitivity compared to the direct method because primary 
antibodies are unlabelled. These retain their specificity and strong signal. There are also an 
increased number of labels per antigen because at least two labelled secondary antibodies can bind 
one primary antibody therefore increasing the intensity which allows the detection of smaller 
amounts of antigen (Ramos-Vara 2005). The technique of indirect immunocytochemistry is as 
follows:  
The cells are first fixed, using paraformaldehyde which is a crosslinking fixative. Fixation is 
important to preserve the cellular structure, to prevent the migration and loss of antigens and to 
stabilise the cell against damaging effects from the subsequent procedure. Paraformaldehyde is a 
good lipid preservative and preserves peptides, general cell structure and interacts with nucleic 
acids with little effect on carbohydrates. This fixative crosslinks proteins by the addition of reactive 
hydroxyl methyl compound between the formalin and uncharged reactive amino groups (-NH and 
NH2). These compounds when in close proximity to other proteins undergo condensation, to 
produce chemically stable methylene bridges that crosslink the proteins (Ramos-Vara 2005). The 
next step is cellular membrane permeabilisation, to allow antibodies entry into the cell through the 
plasma membrane in order to bind to its specific antigen. There are several types of permeabilising 
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agents such as solvents, saponins, lysolecithin and non-ionic detergents. A polyoxyethylene non-
ionic detergent, Triton X-100 was used as it does not denature proteins. This permeabilising agent 
acts through its intercalation within the phospholipid bilayer, where it solubilises lipids and 
transmembrane proteins which disrupt the plasma membrane, creating pores through which 
antibodies can enter the cell. Triton X-100 is particularly useful to detect antigens localised within 
mitochondria and the nucleus (Melan 1999). After permeabilisation, the cells are first exposed to 
blocking buffer that prevents non-specific binding on the secondary antibody. After blocking, the 
cells are exposed to a mouse monoclonal primary antibody which binds with high specificity to 
only one epitope of the antigen it was raised against. The next step is the incubation of the cells with 
a polyclonal secondary antibody labelled with a fluorescent probe. This polyclonal antibody is 
raised in goat, rat, rabbit, horse or monkey, against the animal the primary antibody was raised in ie. 
Anti-mouse IgG. Polyclonal antibodies have higher affinity, wide reactivity but lower specificity for 
epitopes compared to monoclonal antibodies (Ramos-Vara 2005). After this step the chamber slide 
is removed, mounting gel is added to the slide and a coverslip is placed over the cells. The slides are 





Figure 3.5: Diagram of (A) Direct vs (B) Indirect Immunocytochemistry (as prepared by author). 
Fluorescent microscopy is used to visualise objects of interest through fluorescence. A specific 
antigen of interest is labelled with a fluorophore, through immunocytochemistry technique 
mentioned above. A light source will excite the fluorophore, where the molecule absorbs light 




eventually is shed through the emission of fluorescence from the molecule, allowing the electrons to 
move back to ground state (Figure 3.6A). The excitation wavelength is shorter than the emission 
wavelength known as Stoke’s Shift, allowing for the complete filtering out of the excitation light 
without blocking the emitted fluorescence which is then used to visualise the object of interest. The 
fluorescent emission is detected by the fluorescence microscope eye piece and camera, allowing the 








Figure 3.6: Fluorescence Principles. (A) Jablonski Diagram showing energy states of a fluorophore. 
Molecule absorbs light photons and moves to an excited state from ground state. The fluorophore 
emits fluorescence and transitions back to ground state. (B) The absorption and emission spectra of 
the fluorophore fluorescein isothiocyanate (FITC) (Lichtman & Conchello 2005).  
 
To validate the expression of FB1 and TG2 and further characterise apoptotic proteins, 
immunocytochemistry and fluorescent microscopy was performed. An indirect 






















Figure 3.7: Schematic Diagram of Immunocytochemistry using a chamber slide. Fluorescent 
microscopy was used to detect specific probes (Cell Signaling Protocol 2013). 
Wash treated cells 
with 0.1M PBS 
(pH 7.4) twice 
Fix cells with 3.7% 
paraformaldehyde in 
0.1M PBS (pH7.4) 
for 15min at room 
temperature 
Wash once with 
0.1M PBS (pH 7.4) 
Permeabilise the cell 
with 0.1% Triton X-
100 in 0.1M PBS (pH 
7.4) for 15min at 
room temperature 
Wash twice with 
0.1M PBS (pH 7.4) 
Block cells with 3% 
BSA in 0.1M PBS 
(pH 7.4) for 30min at 
37°C 
Wash once with 
0.1M PBS (pH 7.4) 
Incubate cells with diluted 
primary antibody in 3% 
BSA in 0.1M PBS (pH 7.4) 
overnight at 4°C 
 
Wash three times gently 
with 0.1M PBS (pH 7.4) 
Incubate cells with diluted 
secondary antibody in 3% 
BSA in 0.1M PBS (pH 7.4) 
for 2hours at 37°C 
Wash three times gently 
with 0.1M PBS (pH 7.4) 
Remove grid and add Dapi 
Fluoroshield Mounting 
Medium to slide and place 
coverslip over cells. View 




 The cells were seeded at a density of 12.5x10
4 
cells/ml in six 8-well glass chamber slides (housed 
in a petri dish) and then treated with the negative control in the top four wells and 50µM FB1 in the 
bottom four wells for 24 and 72hours at 37°C. After each treatment period, the wells were rinsed 
with 0.1M PBS (pH7.4) twice and then fixed in of 3.7% paraformaldehyde in 0.1M PBS (pH 7.4) 
for 15minutes at 25°C. This was followed by a 0.1M PBS (pH7.4)  rinse then permeabilised in 0.1% 
Triton X-100 in 0.1M PBS (pH 7.4) for 15minutes at 25°C. The wells were then rinsed twice with 
0.1M PBS (pH7.4) and blocked in 3% BSA in 0.1M PBS (pH 7.4) for 30minutes at 37°C. After 
blocking, the wells were incubated overnight with primary antibody in 3% BSA at 4°C. After 
incubation, the wells were then rinsed with 0.1M PBS (pH7.4), treated with secondary antibody, 
and incubated for 2hours at 37°C (Table 3.5). After which the wells were rinsed three times with 
0.1M PBS (pH7.4) and the chamber and rubber gasket were removed. The Dapi Flouroshield 
Mounting medium (100µl) was added onto the slide and a coverslip was gently placed over the cells 
and stored at 4°C. The slides were viewed using a Zeiss Fluorescent Microscope and images were 
taken on the Axiovision imaging system (2010) software. 
Table 3.5: Proteins probed for immunofluorescence microscopy. Slide 1 was incubated for 24 hours 
and slide 2 for 72 hours. Each slide has a negative control and 50µM FB1 treatment well per 
immunofluorescent probe. 










Mouse mAb anti-FB1 
(Abcam: #ab42124) 
Rabbit mAb anti-TG2 
(Sigma: Lot310350) 
1:120 
Goat anti-mouse IgG FITC 
(Sigma-Aldrich: #F0257) 
Goat anti-rabbit IgG 
Tetramethylrhodamine-5-(and 
6)-isothiocyanate (TRITC) 




Mouse mAb anti-β-actin 
conjugated FITC 
(Abcam: #ab6277) 
1:500   
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3.6 Quantitative Polymerase Chain Reaction 
Quantitative Polymerase Chain Reaction (qPCR) allows for the reliable detection and measurement 
of the PCR product generated during each cycle which is directly proportional to the amount of 
template present prior to the PCR reaction. This relationship can be used to determine the amount of 
mRNA present within an experimental sample. The reaction requires a complementary DNA 
(cDNA) template that is synthesised from isolated RNA (described below), Thermus aquaticus 
(Taq) polymerase, deoxyribonucleotide triphosphates (dNTPs), antisense and sense primers. The 
double stranded (ds) cDNA undergoes denaturation to form single-stranded DNA at 95°C. The 
temperature is then cooled to between 55-60°C, which is primer dependent, allowing the primers to 
anneal to the 5’-end of the two single-stranded DNA templates. After annealing, the Taq 
polymerase adds dNTPs to the primers and extends the new DNA strand to create a new dsDNA 
strand. This generates two dsDNA strands from one initial DNA template. This reaction occurs for 
35-40 more cycles to create an exponential amount of PCR product (Bridge 1998). In qPCR a 
SYBR® Green dye is also included within the reaction mix. This dye is a nonsequence specific 
fluorogenic minor groove DNA-binding dye that intercalates into dsDNA. The SYBR Green dye 
exhibits little fluorescence unbound within solution but emits a strong fluorescent signal when it 
intercalates into dsDNA (Figure 3.8). The intensity of the fluorescence is therefore proportional to 
the amount of dsDNA present within the reaction. The fluorescence is measured at the end of the 
elongation step during each PCR cycle, to monitor the increase in the amount of amplified DNA. A 
melt curve (fluorescence as a function of temperature) is also generated, using a LightCycler
TM
 
which increases the specificity of the reaction; this is because each amplicon, at its melting 
temperature, has a characteristic melting peak, which can be used to distinguish it from 










Figure 3.8: Diagram showing the polymerase chain reaction with the intercalation of SYBR Green 
into dsDNA (prepared by author). 
 
During the PCR reaction, the increase in fluorescent emissions could be detected in real time by the 
thermocycler. This emission data collected during PCR was used by the computer software (Bio 
Rad CFX Manager) to construct amplification plots (Figure 3.9). The software first sets up a 
baseline between cycles 3-15 which refers to the PCR cycle, where the reporter fluorescent signal 
accumulated is beneath the detection limit of the instruments. It also calculates ΔRn which is the 
difference between the fluorescent emission of product at each time point and the fluorescent 
emission at baseline. The ΔRn are plotted against the cycle number and do not exceed the baseline 
during each amplification cycle. The software then arbitrarily determined the threshold which was 
calculated as ten times the standard deviation of the baseline signal between cycles 3-15. 
Fluorescent signal detected above this threshold was identified as a real signal and could be used to 
determine the threshold cycle for a sample. The PCR cycle number where the reporter fluorescent 
signal was detected above the minimal detection level i.e. baseline is referred to as the threshold 
cycle (Ct). This Ct value was used to determine the amount of starting template present before the 
reaction. If there was a greater amount of templates prior to the reaction then there would be fewer 
cycles needed in order for the fluorescent signal to be detected above threshold that is statistically 
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significant. This Ct value occurs during the early cycles of PCR exponential phase of the target 
amplification. After many cycles the reaction components are limited therefore the rate of 
amplification decreases until the PCR components are depleted at which time the exponential rate 






Figure 3.9: Model showing a single amplification plot including nomenclature commonly used in 
qPCR (Arya et al. 2005). 
 
Specific errors could be introduced into qPCR experiments as a result of human error such as; 
minor differences in the amount or quality of the RNA starting material or due to different 
efficiencies of cDNA synthesis or PCR amplification. These errors are minimised and sample to 
sample variation are corrected by the simultaneous amplification of a housekeeping gene such as 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The GAPDH could be used as an internal 
reference that RNA sample values are normalised against (Arya et al. 2005). 
The Ct value was used in the comparative threshold method (2
-ΔΔCt 
method) to calculate the relative 
expression level of the target gene against the reference control. This method first normalises the 
target gene against the housekeeping gene ([GAPDH) where ΔCt is the difference between the Ct 
value of target gene and the Ct value of the housekeeping gene (GAPDH). The method then 
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calculates the ΔΔCt which is the difference between the ΔCt value of the sample and the ΔCt value 
of the control. The sample ΔΔCt values are then compared against the control ΔΔCt value of 1 to 
determine the relative expression level of the target gene (Livak & Schmittgen 2001). 
 
3.6.1 Sample Preparation 
Six-well plates were seeded with 5x10
4
 HepG2 cells/ml each and incubated at 37°C for 48hours, 
until the cells were 95% confluent. The flasks were then treated with a negative control, 10µM, 
50µM and 100µM FB1 (in duplicate) in CCM. The one set of plates were incubated for 24hours and 
the other set for 72hours (with 1ml of treatment added after 24hours), both at 37°C. After the 
relevant time intervals each treatment underwent RNA isolation. 
 
3.6.2 Ribonucleic acid Isolation:  
After treatment the CCM was removed from each well and the cells washed with 500µl 0.1M PBS 
(pH7.4) and removed. To each well, 200µl 0.1M PBS (pH7.4) and 500µl Trizol was added, mixed 
gently and incubated for 5minutes at room temperature (RT). Trizol is a monoplastic solution 
comprising of phenol and guanidine isothiocyanate. It disrupts the cell membrane and solubilises 
cell components whilst maintaining RNA integrity (Simms et al. 1993). The 700µl mixture was 
collected in an eppendorf and stored at -80°C for at least an hour {recommended to increase RNA 
yield}. The Trizol samples after incubation at -80°C was thawed at RT. To each sample, 700µl 
Chloroform was added, the eppendorf was shaken vigorously, for approximately 15 seconds and 
then incubated for 2-3minutes at RT. Following incubation, the samples were centrifuged at 12 000 
x g for 5minutes at 4°C. Chloroform was added to allow for the separation of solutions into an 
aqueous phase containing RNA and an organic phase containing DNA and proteins after 
centrifugation (Simms et al. 1993). Whilst working on ice; 350µl aqueous phase was carefully 
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transferred to a new eppendorf. To each sample; 350µl isopropanol, which precipitates out RNA, 
was added and incubated at -80°C for at least one hour {potential indefinite stopping point @ -
80°C}. The samples were then thawed at RT, after incubation and centrifuged at 12 000 x g for 
20minutes at 4°C. The supernatant was removed and discarded. The pellet (flicked to loosen) was 
washed with 525µl 75% cold ethanol and then centrifuged at 7 400 x g for 15minutes at 4°C. The 
ethanol was removed and the pellet left to air dry for 5-10minutes. The RNA pellet was then 
resuspended in 15µl Nuclease-free water and incubated for 2-3minutes at RT. After incubation, the 
sample was placed on ice and the RNA was quantified, using a Nanodrop. The total RNA was 
stored at -80°C until further use. 
 
3.6.3 Ribonucleic acid verification and standardisation:  
The quality of the RNA was checked by running the total RNA samples (5µl RNA with 20µl 5x 
Glotaq) on a 2% Agarose gel with 1x GR green in 1x Tris/Borate/Ethylenediaminetetraacetic acid 
(pH 8.3) buffer at 120V for 30minutes. The gel was visualised by exposing the gel to ultraviolet 
light for 3seconds and the image captured on the GelDoc XRS apparatus (Bio-Rad). Two separate 
bands at 18s and 28s and the A26/A280 ratio was greater than 1.8 therefore verifying the RNA was 
pure. The RNA samples were then standardised to 1µg/µl. 
 
3.6.4 Complementary Deoxyribonucleic synthesis: 
The Bio-Rad iScript
TM
 cDNA Synthesis Kit (#170-8891) was used as per manufacturer’s 
instructions to synthesise cDNA from mRNA. The kit contains an iScript RNase H+ 
Moloney Murine Leukemia Virus-derived reverse transcriptase and is pre-blended with RNase 
inhibitor. The kit also contains an iScript reaction mix which consists of oligo-deoxy-thymine 
nucleotides (dT) and random hexamer primers, dNTPS, buffers and stabilisers. To a PCR tube, 4µl 
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5x iScript reaction mix, 1µl iScript reverse transcriptase, 13µl Nuclease free water and 2µl RNA 
was added per reaction. The PCR tubes containing the complete reaction mix was then incubated 
within the Applied Biosystems’ GeneAmp PCR system 9700 for 5minutes at 25°C and then 
30minutes at 42°C for the random-primer cDNA reaction. This reaction occurs at the Poly-A tail 3’ 
end of the mRNA where the DNA primer will bind to start transcription of cDNA. The reverse 
transcriptase binds at this poly-A tail sequence and adds complementary dNTPs to the DNA primer 
and elongates the cDNA (Figure 3.10). The complete reaction mix was then incubated for 5minutes 






Figure 3.10: Diagram showing the synthesis of complementary DNA (cDNA) from mRNA 
template (prepared by author). 
 
3.6.5 Primer optimisation:  
Primers received from Inqaba Biotechnical Industries (Pty) Ltd were first optimised (Table: 3.6) for 
the Bio-Rad CFX96
TM





Table 3.6: Optimised Concentrations and Annealing Temperature and Time for qPCR primers. 




CHOP sense ACCAAGGGAGAACCAGGAAACG 
1.2µM 55° for 40sec 
CHOP antisense TCACCATTCGGTCAATCAGAGC 
elF2 sense CCTCACCATTTGCCTAAGGA 
1.4µM 55°C for 40sec 
elF2 antisense GGGGGACTTTCCTTCTTCTG 
ATF4 sense GTTCTCCAGCGACAAGGCTA 
1.5µM 65°C for 1min 
ATF4 antisense ATCCTCCTTGCTGTTGTTGG 
TG2 sense ATGAGAAATACCGTGACTGCCTTAC 
800nM 60°C for 1min 
TG2 antisense CAGCTTGCGTTTCTGCTTGG 
Sp1 sense CTTGGTATCATCACAAGCCAGTT 
800nM 60°C for 1min 
Sp1 antisense TCCCTGATGATCCACTGGTAGTA 
 
3.6.6 Reaction Mix Preparation and Thermal Cycling Protocol:  
The iQ
TM
 SYBR® Green Supermix (Bio Rad) contained iTaq DNA polymerase, MgCl2, dNTPs, 
SYBR® Green I dye, stabilisers, enhancers and fluorescein. The iQ
TM
 SYBR® Green Supermix 
and other components were thawed and stored on ice. The master mix was prepared for all 
reactions; this was done by adding all required components except the DNA template according to 







Table 3.7: Components of qPCR master mix 
 Volume per 1x Reaction 
iQ
TM
 SYBR® Green Supermix 6.25µl 
Antisense primer 0.5µl 
Sense primer 0.5µl 
Nuclease free water 3.25µl 
Total 10.5µl 
* add 10µl master mix per well with 2µl cDNA 
The master mix was vortexed to ensure homogeneity and then 10µl master mix was aliquoted into 
each well of the qPCR plate. Good pipetting practice was followed to ensure assay precision and 
accuracy. To each well, 2µl cDNA sample was added and mixed, with a blank where 2µl nuclease 
free water was added to a well. Each sample cDNA was done in triplicate with a GAPDH done to 
normalise the RNA expression (appendix D; table D1-D5). The qPCR plate was then placed within 
the Bio-Rad CFX96
TM
 Real Time System C1000 Touch Thermal Cycler and the following protocol 
was selected {with a variation in the annealing temperature and time according to table for the 
different primers}. The polymerase activation and DNA denaturation was set at 95°C for 3minutes. 
The amplification step of 35-40 cycles included: denaturation at 95°C for 10-15sec and 
annealing/extension according to Table 3.6. The Melt curve analysis occurred between 55-95°C in 
0.5°C increments every 2-5sec/step (as per manufacturer’s instructions). 
The Ct value was calculated in Microsoft Excel using the 2
-ΔΔCt 
Method as described above to 






3.7 Sample Preparation for Flow Cytometry and Luminometry 
Four small flasks were seeded with 5x10
4
 HepG2 cells/ml each and incubated at 37°C for 48hours, 
until the cells were 95% confluent. The flasks were then treated with 0µM (used as the negative 
control), 10µM, 50µM and 100µM FB1 (in duplicate) in serum-containing media (CCM). The flasks 
were incubated for 72hours, both at 37°C. After the relevant treatment period, the CCM was 
removed and washed with 0.1M PBS (pH7.4) three times. The cells were then trypisinised by 
adding 2ml trypsin and incubating the cells for 5minutes at 37°C. After incubation, the trypsin was 
removed and 2ml CCM was added per flask, the flask was shaken to remove the cells attached to 
the flask into the CCM. The cell suspension was then collected and the cells counted using the 
Trypan Blue method. The cells were then centrifuged at 450 x g for 5minutes at RT, the supernatant 
discarded and resuspended in 0.1M PBS (pH7.4) where the cells were adjusted to 1x10
6 
cells/ml. 
These cells were then used in Flow cytometry and Luminometry and the results measured, using 
relative light units (RLU). 
 
3.8 Flow Cytometry 
This technique allows for the measurement of properties of individual particles. It does this through 
the use of a fluids system (Figure 3.11A) which organises the sample of randomly distributed 
particles into a single stream of particles. This is known as hydrodynamic focusing which occurs as 
a result of a massive drag effect on the narrow central chamber set up by the outer sheath fluid 
moving at a greater velocity than the sample within the central chamber. The particles in single file 
are then passed through one or more beams of light from either an argon or diode laser which 
produces light at 488nm and 635nm wavelengths respectively. This light excites the fluorochromes 
attached to the particle which causes a fluorescent emission to be produced which is detected in 
fluorescence channels (FL-). The  Fluorescence-activated cell sorting (FACS) Calibur flow 
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cytometer has four fluorescent channels (Figure 3.11B): FL-1 Green which detect fluorescent 
emissions between wavelengths 515-545nm, FL-2 Yellow detects 564-606nm wavelengths, FL-3 
Red detects fluorescent emissions with wavelengths greater than 670nm and FL-4 Orange which 
detects wavelengths between 653 and 669nm. Each fluorescent channel uses a separate optical 
detector which is controlled by optical filters that block through absorption specific wavelengths 
whilst transmitting others. For example the FL-1 channel filter will transmit wavelengths between 
515-545nm whilst blocking all other wavelengths it comes into contact with. After the 
fluorochrome is excited and emits a fluorescent signal, this signal is transmitted to the relevant FL 
channel; at this detector the light generates a small current only a few microamperes in size. The 
currents associated voltage has amplitude directly proportional to the number of light photons 
received at the detector. The voltage received at the detector is then amplified by a number of linear 
or logarithmic amplifiers and by analogue to digital convertors that generate an electrical signal 
large enough to be plotted graphically. One measurement from a detector is known as a parameter, 
for example fluorescence. The data generated at each parameter is known as an event which refers 
to the number of cells displaying the specific characteristic. During flow cytometry 50 000 events 







Figure 3.11: Diagram illustrating (A) Hydrodynamic Focusing (Rahman 2006) and (B) the setup of 




The data acquired during flow cytometry was the analysed using FlowJo 7.1 software (Tree Star 
Inc., Ashland, USA). It is important to first selectively visualise the cells of interest and eliminate 
other unwanted particles such as debris and dead cells. This is done through the process called 
gating. Once the cells of interest have been gated, the results call be visualised either as a one 
parameter histogram where the fluorescence is plotted against the number of cells. This is used in 
the cluster of differentiation 95 (CD95) analysis (Figure 3.12A). The data could also be visualised 
using a two parameter dot plot which displays two parameters against each other for example in the 
Annexin-V-FLOUS experiment: Annexin-V- FITC vs Propidium Iodide (Figure 3.12B) and in 1st 




Figure 3.12: Graphs showing (A) a one parameter histogram (Biolegend 2013), (B) Annexin-V-
FITC vs PI dual parameter dot plot (Chacko et al. 2010) and (C) JC-1  FL-1 vs JC-1 FL-2 dual 
parameter dot plot (BDBiosciences 2013). 
 
3.8.1 Annexin-V-Fluorescent 
The Annexin-V-Fluorescent (FLOUS) Staining Kit (Roche) was used to detect apoptotic cells and 
differentiate out necrotic cells due to FB1 treatment. During the early stages of apoptosis there are 
plasma alterations which include the translocation of phosphatidylserine (PS) from the inner part of 
the membrane to the outer part of the membrane therefore exposing PS to the external cell 
environment. The PS on the outer surface of the cell is analysed using an Annexin-V-FLOUS probe 
which binds in a calcium-dependent manner to the negatively charged PS surface with high 
(A) (C) (B) 
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specificity. To differentiate the necrotic cells, as these cells also expose PS on their outer surface 
due to their damaged plasma membrane, Propidium Iodide (PI) dye is used simultaneously to stain 
leaky DNA in necrotic cells only (Figure 3.13). Annexin-V-FLOUS has an excitation wavelength of 
488nm and emission wavelength of 518nm. Propidium Iodide has an excitation wavelength of 488-






Figure 3.13: Annexin-V-FITC binding to phosphatidyl serine in apoptotic and necrotic cells with 
Propidium Iodide staining of leaky DNA in necrotic cells thereby differentiating apoptotic from 
necrotic cells (prepared by author). 
 
The Annexin-V-FLOUS labelling reagent was pre-diluted in 1ml incubation buffer and added to 
20µl PI solution. The cells (prepared above [section: 3.7]) were centrifuged at 200 x g for 5minutes 
and re-suspended in 100µl Annexin-V-FLOUS labelling solution and incubated at 15-25°C for 10-
15minutes. To the cell suspension 0.5ml incubation buffer was added. A positive control with 
HepG2 cells treated with 5µM Campthothecin was done as well (Appendix E; table and figure E1). 
The cells were analysed using the flow cytometer (FACS Calibur, BD Biosciences, Johannesburg, 
South Africa) at 488nm excitation with a 515nm bandpass filter for fluorescence detection and a 
filter >600nm for PI detection. Data was collected for 50000 events per sample and analysed with 
FlowJo 7.1 software (Tree Star Inc., Ashland, USA). 
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3.8.2 Mitochondrial Membrane Potential Detection 
The BD
TM
 MitoScreen Kit from BD Biosciences was used to detect the mitochondrial membrane 
potential after HepG2 cells were treated with varying concentrations of FB1. This kit contains JC-1 
fluorochromes that are used to detect mitochondrial membrane potential. JC-1 exists in two states, 
either as a monomer in cases of low dye concentrations or as aggregates when there is a high dye 
concentration; each having their own emission spectra. The JC-1 monomers and aggregates both 
emit fluorescence in the Green (FL-1) channel of the flow cytometer. When live cells are exposed 
to JC-1, this fluorochrome penetrates the plasma membrane of the cell and enters the cytoplasm. As 
healthy cells are known to have polarised mitochondrial membrane potentials, the JC-1 is rapidly 
taken up into the mitochondria thus increasing the concentration gradient within the mitochondria 
which causes the formation of JC-1 aggregates. These JC-1 aggregates show a red spectral shift 
therefore increasing red fluorescence emission which is measured on the Red (FL-2) Channel of the 
flow cytometer. In damaged or apoptotic cells the mitochondrial membrane potential becomes 
depolarised and as a result the JC-1 monomers are unable to enter the mitochondria; therefore JC-1 
remains as monomers within the cytoplasm (Figure 3.14). As monomers do not show a red spectral 
shift there is decreased fluorescence in the FL-2 channel and increased green fluorescence in the 
FL-1 channel.  As a result polarised cells will emit fluorescence in both FL-1 and FL-2 channels 
whilst depolarised cells will emit fluorescence in FL-1 channel with minimal to no fluorescence in 
FL-2 channel. The JC-1 fluorochrome is typically excited with a 488nm argon ion laser and the 












Figure 3.14: Mitochondrial membrane potential (MMP) and JC-1 fluorochrome reaction. Left: 
Depolarised MMP with JC-1 monomers. Right: Polarised MMP with JC-1 aggregates within 
mitochondria and JC-1 monomers in cytoplasm (prepared by author). 
 
Initially the kit reagents were prepared: The 10x Assay Buffer was first diluted to 1x solution and 
warmed to 37°C prior to use. This is used as a reaction buffer and to wash cells. The JC-1 was 
reconstituted by adding 125µl DMSO to form a stock solution; which is either diluted into a 
working solution or stored at -20°C. The working solution was prepared by the dilution of JC-1 
stock solution with the 1x Assay Buffer. The cells prepared as described above were centrifuged at 
400 x g for 5minutes at RT and the supernatant removed. The freshly prepared JC-1 Working 
Solution was added to the cell pellet, re-suspended gently and vortexed to remove cell-to-cell 
clumping (Figure 3.15). The cells in JC-1 working solution were incubated at 37°C for 15minutes 
and washed twice. The first wash was done by adding 2ml 1x Assay Buffer to each tube, the cells 
were then vortexed and centrifuged at 400 x g for 5minutes and the supernatant was carefully 
removed. The second wash was done by the addition of 1ml 1x Assay Buffer, the cells were re-
suspended gently, vortexed and centrifuged at 400 x g for 5minutes. The cells were resuspended in 
0.5ml 1x Assay Buffer, vortexed and then analysed by flow cytometry (FACS Calibur, BD 
Biosciences, Johannesburg, South Africa). A positive control with HepG2 cells treated with 5µM 
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Campthothecin was done as well (Appendix E; table and figure E2). Data was collected for 50000 







Figure 3.15: Overview of Reagent Preparation and JC-1 staining of cells used for Flow cytometry 
analysis of mitochondrial membrane potential (BDbiosciences 2013b). 
 
3.9 Luminometry 
3.9.1 The CellTiter-Glo® Luminescent Cell Viability Assay (Promega) 
This luminescent assay is used to identify the number of viable, metabolically active cells through 
the quantitation of ATP present and its relation to metabolic functioning of the cells. The amount of 
ATP present is proportional to the number of viable cells. The assay is based on the luciferase 
reaction where luciferase in the presence of ATP, magnesium (Mg
2+
) and molecular oxygen will 
generate luminescence (Figure 3.16). The greater the luminescence; the greater the amount of ATP; 








Figure 3.16: The luciferase reaction. The enzyme, luciferase catalyses the mono-oxygenation of 
luciferin; in the presence of Mg
2+
, ATP and molecular oxygen (Promega Protocol). 
 
3.9.2 Caspase -Glo® 3/7, 8 and 9 Assay (Promega) 
This luminescent assay measures the activity of caspase 3/7, 8 and 9 which are members of the 
cysteine aspartic family that are important affecters and effectors in apoptosis in mammalian cells. 
This assay provides luminogenic caspase 3/7, 8 and 9 substrates conjugated with a tetrapeptide 
sequence aspartate-glutamate-valine-aspartate (DEVD). This DEVD sequence is cleaved by active 
caspases which allows for the luciferase reaction that produces a “glow-type’ luminescent signal 
which is quantified by the luminometer (Figure 3.17). The amount of luminescence is proportional 






Figure 3.17: Caspase 3/7, 8 and 9 cleavage of the DEVD sequence to produce aminoluciferin that 
undergoes the luciferase reaction and produces light (Promega Protocol). 
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The method for the Caspase- Glo 3/7, 8, 9 and CellTiter-Glo Cell Viabilty assays were performed 
(Figure 3.18). The Caspase-Glo 3/7, 8, 9 and CellTiter-Glo buffer and lyophilised Caspase-Glo 3/7, 
8, 9 and CellTiter-Glo substrate was equilibrated to RT. The Caspase-Glo 3/7, 8, 9 and CellTiter-
Glo Reagent was prepared by the addition of equal amounts of Caspase-Glo 3/7, 8, 9 and CellTiter-
Glo buffer and Caspase-Glo 3/7, 8, 9 and CellTiter-Glo lyophilised substrate. To each well of the 
white-walled 96-well plate, 100µl of treated cells (as prepared above [section 3.7]) was added and 
100µl Caspase-Glo 3/7, 8, 9 and CellTiter-Glo reagent was added. The plate was then incubated at 
RT for 30minutes. The luminescence of each sample was then measured using a Turner Biosystems 





Figure 3.18: Flow Diagram showing the Promega Caspase-Glo® 3/7, 8, 9 (Left) and the Promega 
CellTiter-Glo® (Right) Reagent Preparation (Promega Protocol). 
 
3.10 Statistical Analysis 
The data was reported as mean ± standard deviation. The data was analysed by the GraphPad 
prism5 software, Image J software and Microsoft Excel 2010. The student unpaired t test and one-
way analysis of variance (ANOVA) was done on all data to determine the significance (p<0.05) 





4.1 Fumonisin B1-Tissue transglutaminase interaction 
4.1.1 Fumonisin B1 incorporation into Fibronectin- Tissue transglutaminase Guinea pig liver  
         Standard 
The Coomassie Blue stain and western blotting was performed to determine whether FB1 was 
incorporated in fibronectin as a result of gpl TG2 activation. This assay tests gpl TG2 activity. The 
Coomassie blue staining (Figure 4.1A and 4.2A) is to reveal equal loading of fibronectin in all the 
wells. Western blots were then probed for anti-FB1 (Figure 4.1B and 4.2B). The no calcium reaction 
mix (Figure 4.1B) showed no bands present after 15minutes reaction time but slight bands present 
at about 270kDa following the 1hour reaction time. The high calcium reaction mix (Figure 4.2B) 
showed a dose and time-dependent increase in band densities where FB1 bands are prominent for 
1000µM FB1 treatments after 1hour reaction time. These bands show that FB1 has been covalently 



















Figure 4.1: Fumonisin B1 incorporation into fibronectin in No Calcium Reaction Mix (using gpl 
standard of TG2) – adaptation of TG2 activity assay using SDS-PAGE (Coomassie Blue staining to 
show equal loading, A) and Western Blotting to probe for FB1 (B) proteins using a mouse anti-FB1 
(1:1000) primary antibody and anti-mouse (1:5000) secondary antibody. Precision plus protein 











Figure 4.2: Fumonisin B1 incorporation into fibronectin in High Calcium Reaction Mix (using gpl 
standard of TG2) – adaptation of TG2 activity assay using SDS-PAGE (Coomassie Blue staining to 
show equal loading, A) and Western Blotting to probe for FB1 (B) proteins using a mouse anti-FB1 
(1:1000) primary antibody and anti-mouse (1:5000) secondary antibody. Precision plus protein 
standard (Bio-Rad: #161-0373) was used as the molecular weight marker. 
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4.1.2 Fumonisin B1 incorporation into Fibronectin- HEPG2 Cell Homogenates 
Western blotting was performed to investigate TG2 activity within HepG2 cells after exposure to 
FB1. This method tests TG2 activity by investigating whether FB1 was incorporated in fibronectin. 
The TG2 enzyme was catalytically activated in the high calcium reaction and crosslinked FB1 into 
the fibronectin as seen by the bands in the western blot probed for anti-FB1 (Figure 4.3B) where 
there is an increase in FB1 crosslinking. The no calcium reaction mix (Figure 4.3A) had slight FB1 









Figure 4.3: Fumonisin B1 incorporation into fibronectin (using HepG2 cell homogenate) – 
adaptation of TG2 activity assay using SDS-PAGE and Western Blotting to probe for FB1 (A and 
B) proteins using a mouse anti-FB1 (1:1000) primary antibodies and anti-mouse (1:5000) secondary 
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4.1.3 Tissue transglutaminase Expression – Western blotting 
To determine whether TG2 activity was induced in HepG2 cells as a result of FB1 exposure, 
western blotting was performed and the results validated using fluorescent microscopy. Tissue 
transglutaminase expression is increased after 24hours (Figure 4.4A). After 72hours, there is an 
increase of TG2 expression observed (Figure 4.4B). These results were validated in the 
immunofluorescent photographs (Figure 4.5 and 4.6) which show TG2 up-regulation after 24 and 
72hours (Figure 4.5E and 4.6E) with co-localisation of TG2 and FB1 being seen in the merged 
image (Figure 4.5F and 4.6F). The FB1 is seen to be incorporated intracellularly (Figure 4.5D and 






Figure 4.4: Tissue transglutaminase expression in HepG2 cells following treatment with 0µM, 
10µM, 50µM and 100µM FB1 incubated for 24 and 72 hours at 37°C. The concentration of the TG2 
gpl standard is 10µg/ml. Western Blotting was used to probe for TG2 proteins using rabbit anti-
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Figure 4.5: Fumonisin B1 and Tissue transglutaminase co-localisation in HepG2 cells after 
treatment with FB1 at concentrations of 0 and 50µM for 24 hours, fluorescent microscopy validation 
viewed at 100x oil immersion using Axiovision software. Images A and D represent FB1 expression 
in green (FITC), images B and E represent TG2 expression in Red (TRITC) and images C and F 































Figure 4.6: Fumonisin B1 and Tissue transglutaminase co-localisation in HepG2 cells after 
treatment with FB1 at concentrations of 0 and 50µM for 72hours, fluorescent microscopy validation 
viewed at 100x oil immersion using Axiovision software. Images A and D represent FB1 expression 
in green (FITC), images B and E represent TG2 expression in Red (TRITC) and images C and F 
represents the co-localised FB1 and TG2 in yellow with Dapi showing the cell’s nucleus. Bar equals 
40µm. 
 
4.2 Fumonisin B1 induces cytoskeletal damage 
To determine whether the cytoskeleton is damaged when HepG2 cells are exposed to FB1; a β-actin 
antibody was used. The actin (Figure 4.7A and C) is structurally intact in the controls with 
disruption being observed after 24 and 72hour 50µM FB1 treatment (Figure 4.7B and D).  
 























Figure 4.7: Actin expression in HepG2 cells after FB1 treatment with 0 and 50µM concentrations for 
24 and 72hours. Fluorescent microscopy images captured at 40x magnification using Axiovision 
software. Green FITC (A, B, C and D) represents actin. Bar equals 40µm. 
 
4.3 Endoplasmic Reticulum Stress Pathway Induction 
4.3.1 Fumonisin B1 effect on Protein kinase ribonucleic-like endoplasmic reticulum kinase –  
         Endoplasmic Reticulum Stress Pathway 
The effect of FB1 on the PERK ER stress pathway was investigated using western blotting and 
qPCR techniques. The expression of total PERK was increased after 24hours at 10µM and 50µM 
FB1 concentrations with a decrease in total PERK observed at 100µM FB1 compared to the control. 
However, after 72hours the total PERK expression was shown to decrease across all concentrations 
of FB1 relative to the control (Figure 4.8). There was an overall increase in phosphorylated eIF2α 
(p-eIF2α) across both treatment periods and at all FB1 concentrations (Figure 4.9); however the 
basal level of p-eIF2α expression at the 24hour treatment is higher than after 72hours. The mRNA 











levels of eIF2α showed a corresponding significant increase in eIF2α mRNA expression at 50µM 
(p<0.05) and 100µM FB1 (p<0.05) at the 72hours treatment period. However, a significant decrease 
in eIF2α mRNA levels was observed at 10µM (p<0.05) and 100µM FB1 (p<0.05) after the 24hour 
treatment period (Figure 4.10). A marker of ER stress, CHOP showed a significant increase in 
mRNA expression at all concentrations of FB1 (p<0.05) after 72hours (Figure 4.11). There was no 
change in CHOP mRNA expression levels observed after 24hours (Figure 4.11). A downstream 
marker of the PERK ER stress pathway ATF4 (Figure 4.12) showed a significant decrease in 














Figure 4.8: The protein expression of total PERK in HepG2 cells after treatment with 
concentrations 0µM, 10µM, 50µM and 100µM of FB1 after 24hours (red bars) and 72hours (blue 
bars). Results were normalised against β-actin. The mean relative band densities are represented by 
the bars. Representative of two separate experiments. 
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Figure 4.9: The protein expression of p-eIF2 in HepG2 cells after treatment with concentrations 
0µM, 10µM, 50µM and 100µM of FB1 after 24hours (red bars) and 72hours (blue bars). Results 
were normalised against β-actin. The mean relative band densities are represented by the bars. 
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Figure 4.10: The expression of eIF2 mRNA in HepG2 cells after treatment with 0µM, 10µM, 50µM 
and 100µM FB1 for 24hours (red bars) and 72hours (blue bars) (Above). Mean ± standard error. 
Statistical significance: ** shows p<0.001 and *** shows p<0.0001. The melt curves for eIF2α and 
GAPDH amplicons show specificity of the primers and no artefacts were present (Below). 




























































Figure 4.11: The expression of CHOP mRNA in HepG2 cells after treatment with 0µM, 10µM, 
50µM and 100µM FB1 for 24hours (red bars) and 72hours (blue bars) (Above). Mean ± standard 
error. Statistical significance * shows p<0.05 and **shows p<0.001. The melt curves for CHOP and 
GAPDH amplicons show specificity of the primers and no artefacts were present (Below). 


























































Figure 4.12: The expression of ATF4 mRNA in HepG2 cells after treatment with 0µM, 10µM, 
50µM and 100µM FB1 for 24hours (red bars) and 72hours (blue bars) (Above). Mean ± standard 
error. Statistical significance: *** shows p<0.0001. The melt curves for ATF4 and GAPDH 
amplicons show specificity of the primers and no artefacts were present (Below). Representative of 













































4.3.2 Nuclear factor kappa B phosphorylation and Tissue transglutaminase induction as a result of  
         Endoplasmic Reticulum stress. 
The TG2 and NFkB activity were investigated after subcellular fractionation of HepG2 cells treated 
with FB1. After 24hours there was decrease in phosphorylation of nuclear NFkB at 10µM and 
100µM FB1 whilst at 50µM FB1 there was an increase in phosphorylation of nuclear NFkB. The 
corresponding cytoplasmic NFkB showed a decrease in phosphorylation at 10µM and 50µM FB1 
with an increase observed at 100µM FB1 with a corresponding decrease in cytoplasmic p-NFkB. 
However after 72hours there was an increase in the basal level of phosphorylation of NFkB as well 
as increased phosphorylation observed in the nuclear NFkB with a corresponding decrease in 
cytosolic p-NFkB (Figure 4.13). The expression of nuclear TG2 increased after 24hours with a 
corresponding increase in cytosolic TG2 expression (Figure 4.14). The nuclear TG2 mRNA 
expression was significantly reduced (p<0.05) after 24hours (Figure 4.15). However, after 72hours 
of FB1 treatment there was an increase in nuclear TG2 observed and a slight decrease in the 
corresponding cytosolic TG2 expression (Figure 4.14). The expression of nuclear TG2 mRNA was 
significantly increased at 10µM FB1 (p<0.05), whilst significantly reduced at 50µM FB1 (p<0.05) 
and showed an increase in expression at 100µM FB1 treatment although it was not significant 
(Figure 4.15). A potential downstream effector of TG2 apoptosis, Sp1 showed a significant decrease 
in mRNA expression after 24hours at 50µM (p<0.05) and 100µM FB1 (p<0.05) (this is not true for 
10µM FB1). A significant increase in Sp1 expression after 72hours at 10µM FB1 (p<0.05)  was 




























Figure 4.13: The protein expression of p-NFkB in the nuclear and cytosolic fraction of HepG2 cells 
treated with 0µM, 10µM, 50µM and 100µM FB1 after 24hours and 72hours. Results were 
normalised against β-actin. The bars represent the mean relative band densities. Representative of 
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Figure 4.14: The protein expression of TG2 in the nuclear and cytosolic fraction of HepG2 cells 
treated with 0µM, 10µM, 50µM and 100µM FB1 after 24hours and 72hours. Results were 
normalised against β-actin. The bars represent the mean relative band densities. Representative of 

































     Nuclear Fraction             Cytosolic Fraction 


























Figure 4.15: The expression of TG2 mRNA in HepG2 cells after treatment with 0µM, 10µM, 50µM 
and 100µM FB1 for 24hours (red bars) and 72hours (blue bars) (Above). Mean ± standard error. 
Statistical significance ** shows p<0.001 and ***shows p<0.0001. The melt curves for TG2 and 
GAPDH amplicons show specificity of the primers and no artefacts were present (Below). 





























































Figure 4.16: The expression of Sp1 mRNA in HepG2 cells after treatment with 0µM, 10µM, 50µM 
and 100µM FB1 for 24hours (red bars) and 72hours (blue bars) (Above). Mean ± standard error. 
Statistical significance * shows p<0.05 and **shows p<0.001. The melt curves for Sp1 and GAPDH 
amplicons show specificity of the primers and no artefacts were present (Below). Representative of 







































4.4 Apoptotic effect of Fumonisin B1 
The apoptotic effect of FB1 was investigated after 72hour treatment of HepG2 cells with varying 
concentrations of FB1. Caspase’s are initiators and effectors of the apoptotic pathway and were 
investigated using luminometry. Caspases 3 and 8 (Figure 4.17 and 18) activities were significantly 
reduced at 100µM FB1 (p<0.05) and 50µM FB1 (p<0.05) (caspase 8 only). A decrease in caspase 9 
activity was observed although not significant (Figure 4.19). There was a significant reduction in 
ATP levels after 100µM FB1 (p<0.05) treatment (Figure 4.20). The Annexin-V-FITC and JC-1 
MitoScreen experiments were done to determine the percentage of apoptotic, live cells and 
depolarised mitochondria present after 72hours of FB1 treatment. The results showed that there was 
a significant increase in apoptotic cells when HepG2 cells were treated with 10µM FB1 (p<0.05) 
(Figure 4.21) with a corresponding significant decrease (p<0.05) in the amount of healthy cells 
(Figure 4.22). There is also an increase in the percentage of depolarised mitochondria with the 
10µM FB1 (p<0.05) treatment (Figure 4.23). However, when HepG2 cells are treated with 50µM of 
FB1 there is a decrease in the percentage of apoptotic cells (Figure 4.21) with a corresponding 
significant increase (p<0.05) in healthy cells (Figure 4.22) and a significant decrease in depolarised 



















Figure 4.17: Caspase 3/7 activity in HepG2 cells treated with 0µM, 10µM, 50µM and 100µM FB1 
for 72hours. Mean ± Standard error. Statistical significance: ** shows p<0.001. Representative of 










Figure 4.18: Caspase 8 activity in HepG2 cells treated with 0µM, 10µM, 50µM and 100µM FB1 for 
72hours. Mean ± Standard error. Statistical significance: * shows p<0.05. Representative of three 
separate experiments. 





























































Figure 4.19: Caspase 9 activity in HepG2 cells treated with 0µM, 10µM, 50µM and 100µM FB1 for 










Figure 4.20: The ATP levels in HepG2 cells treated with 0µM, 10µM, 50µM and 100µM FB1 for 
72hours. Mean ± Standard error. Statistical significance: *** shows p<0.0001. Representative of 
three separate experiments. 
 



















































Figure 4.21: The percentage of Annexin positive or apoptotic cells in HepG2 cells treated with 
0µM, 10µM, 50µM and 100µM FB1 for 72hours. Mean ± Standard error. Statistical significance: 










Figure 4.22: The percentage of healthy/live cells in HepG2 cells treated with 0µM, 10µM, 50µM 
and 100µM FB1 for 72hours. Mean ± Standard error. Statistical significance: * shows p<0.05; *** 
shows p<0.0001. Representative of three separate experiments. 














































Figure 4.23: The percentage of depolarised mitochondria in HepG2 cells treated with 0µM, 10µM, 
50µM and 100µM FB1 for 72hours. Mean ± Standard error. Statistical significance: ** shows 






























Fumonisin B1 toxicity is well characterised to be a result of ceramide synthase inhibition which 
interrupts sphingolipid biosynthesis (Grenier et al. 2012) leading to the disruption of the cell and its 
plasma membrane; which is a possible cause of cell stress leading to ER stress. This study 
investigated the possible role of TG2 induction by FB1 and the effect FB1 toxicity has on the ER 
stress pathway in HepG2 cells. A novel association between FB1 and TG2 was observed (Figure 
4.1, 4.2, 4.3 and 4.5) in the HepG2 liver cells where FB1 induced TG2 expression and activity, with 
FB1 acting as a potential crosslinking substrate for this enzyme.  Further, the ability of FB1 to 
induce ER stress was investigated using western blotting and qPCR (Figure 4.8-4.12); with TG2 
and NFkB involvement being investigated by western blotting and qPCR (Figure 4.13-4.16). 
Apoptotic markers were determined using   luminometry (caspase assays) (Figure 4.17-4.20), and 
flow cytometry [Annexin-V-FITC (Figure 4.21 and 4.22) and the JC-1 MitoScreen assays (Figure 
4.23)]. 
 
The ubiquitous enzyme TG2 catalyses the post-translational modifications of proteins through a 
transamidation reaction which results from the acyl transfer between a ƴ-carboxyamide glutamine 
residue (acyl donor) and a lysine Ɛ-amino residue of a primary amine (acyl acceptor) which forms a 
proteinase-resistant covalent N-ƴ-glutamyl-Ɛ-lysyl-isopeptide bond (crosslink) (Martin et al. 2012); 
with the crosslinked protein product being a higher molecular mass (Park et al. 2010). The TG2 
activity assay demonstrated a novel interaction between FB1 and the calcium-dependent catalytic 
activity of TG2 (Figure 4.1, 4.2, 4.3 and 4.5), where TG2 appears to catalytically incorporate FB1 
into fibronectin-crosslinked high molecular polymers. This observation exposed FB1 as a possible 
substrate for TG2 activity (Figure 4.1, 4.2 and 4.3). Fibronectin was used as it is a well 
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characterised extracellular matrix protein that TG2 binds and crosslinks with high affinity (Griffin 
et al. 2002). A covalent association between fibronectin (acyl donor) and FB1 (acyl acceptor) was 
observed because through SDS-PAGE experimentation the bond was not broken and the resulting 
crosslinked-fibronectin had a higher molecular weight (Park et al. 2010). The results showed that 
TG2 activity is dependent on calcium (Figure 4.1B and 4.2B), FB1 concentration and time (Figure 
4.2B and 4.3B). High calcium conditions are essential as calcium activates TG2 through the 
conformational change which exposes its active site allowing the reaction to occur (Park et al. 
2010). Dependence on FB1 and time was seen as increasing the availability of the substrate and the 
time for the reaction to occur increased FB1 incorporation into fibronectin. This association was 
further validated using immunofluorescent microscopy (Figure 4.5 and 4.6) which showed TG2 up-
regulation by FB1 (Figure 4.5D and 4.6D) and co-localisation of FB1 and TG2 (Figure 4.5F and 
4.6F) where FB1 may be catalytically incorporated intracellularly when treated with 50µM FB1. As 
FB1 toxicity has been characterised to disrupt membrane-sphingolipid metabolism (Heidtmann-
Bemvenuti et al. 2011), the activity of TG2 to incorporate FB1 into the plasma membrane (Figure 
4.5F and 4.6F) may have a possible novel role of TG2 in FB1-associated stress response signalling 
pathways (Giussani et al. 2006). 
 
The inhibition of ceramide synthase due to FB1 toxicity leads to decreased ceramide formation and 
a decrease in complex sphingolipids, which are essential components of the plasma membrane 
(Heidtmann-Bemvenuti et al. 2011). Fumonisin B1 caused cytoskeletal damage and disrupted cell 
membranes in HepG2 cells (Figure 4.7). The activation of TG2 (Figure 4.3) is a calcium-dependent 
occurrence where calcium levels need to be above 700-800nM which occurs only in 
supraphysiological conditions i.e. when the cell is damaged (Kuo et al. 2011). The ER acts as a 
major reservoir of intracellular calcium and therefore plays a critical role in calcium homeostasis 
(Hetz 2012; Hotamisligil 2010). Therefore due to high levels of calcium required for TG2 activation 
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it can be suggested that the ER function is disrupted leading to the activation of the ER stress 
pathway.  
 
The ER stress pathway or UPR is activated when protein folding becomes compromised 
(Rutkowski & Kaufman 2004). The PERK arm of the UPR is activated upon BiP dissociation as a 
result of increased UP (Hotamisligil 2010; Pagliassotti 2012). Upon PERK activation, it 
phosphorylates serine 51 on eIF2α which leads to protein synthesis attenuation (Lasfargues et al. 
2013). The phosphorylation of e-IF2α stimulates the translation of ATF4 mRNA (Lasfargues et al. 
2013) which controls selective pro-survival genes (Hetz 2012). A transcription factor CHOP is 
upregulated by ATF4 and is involved in ER stress-induced apoptosis (Lasfargues et al. 2013). The 
24hour FB1 treatment showed an increase in total PERK at 10µM (Figure 4.8), an increase in p-
eIF2α (Figure 4.9) with a corresponding significant decrease in eIF2α mRNA expression at 10µM 
FB1 (p<0.05) (Figure 4.10) and an increase in CHOP (Figure 4.11) mRNA expression although not 
significant. After 72hours however total PERK was decreased (Figure 4.8) and there was a 
reduction in the basal level of p-eIF2α although still activated (Figure 4.9) with a significant 
increase in eIF2α mRNA expression at 50µM (p<0.05) and 100µM FB1 (p<0.05) (Figure 4.10). At 
50µM (p<0.05) and 100µM FB1 (p<0.05) CHOP mRNA expression was also significantly induced 
(Figure 4.11). These results are in agreement with a study by  Aflaki et al. (2012) on macrophages. 
This shows that FB1 induced ER stress via the PERK pathway with increased ER stress being 
observed after 72hours due to the significant increase in CHOP after 72hours. However unlike 
Aflaki et al. (2012), this study in HepG2 cells showed a significant decrease in ATF4 mRNA 
expression (p<0.05)  both at 24 and 72hours (Figure 4.12). This could suggest that the PERK-eIF2α 
pathway was activated but p-eIF2α levels were too low to impair the initiation at the second µORF 
of ATF4 gene (Lasfargues et al. 2013) therefore preventing its transcription. The genes induced 
downstream of ATF4 transcription are important for the cell to recover from various stresses 
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(Rutkowski & Kaufman 2004); according to Aflaki et al. (2012) FB1 reduced but failed to abolish 
the ER stress in macrophages. This could potentially explain the reduction in ATF4 observed in this 
liver model as pro-survival downstream genes of ATF4 would not be transcribed therefore 
preventing recovery of ER stress in HepG2 cells. However this requires further investigation due to 
the difference in cell lines; although the liver is an immune organ and FB1 has shown to be 
immunotoxic in vitro (Stockmann-Juvala et al. 2008), the effects on hepatocarcinoma cells would 
differ. As ATF4 is a known inducer of CHOP (Rutkowski & Kaufman 2004) and ATF4 showed a 
significant decrease (p<0.05)  in mRNA expression (Figure 4.12) but CHOP showed a significant 
increase (p<0.05) in mRNA expression (Figure 4.11), further studies are required to identify other 
transcription factors that could induce CHOP. ATF6 is thought to also induce CHOP, so its 
induction could be a result of the other arms of the UPR (Rutkowski & Kaufman 2004). 
 
It has been reported that ER stress activates NFkB (Tam et al. 2012). Nuclear factor kappa B 
activation has been linked to PERK-mediated eIF2α phosphorylation; where the attenuation of 
translation leads to a rapid decrease in IkBα due to its relatively short-half life and the inhibition of 
translation (Tam et al. 2012). Fumonisin B1 treatment showed a decrease in both nuclear NFkB and 
cytosolic NFkB after 24hours at 10µM FB1 (Figure 4.13). However, after 72hours there was an 
increase in the basal level of NFkB as well as an increase in nuclear NFkB with a corresponding 
decrease in cytosolic NFkB at 10µM and 50µM FB1 (Figure 4.13), evidence for PERK activation of 
NFkB and nuclear translocation. Nuclear factor kappa B is a transcriptional inducer of TG2 where 
NFkB binds the TGM2 promoter gene directly and induces TG2 transcription (Ientile et al. 2007). 
Fumonisin B1 treatment showed an increase in nTG2 expression with a corresponding decrease in 
cytosolic TG2 (Figure 4.14) and a significant decrease in nTG2 mRNA expression (p<0.05) (Figure 
4.15) which correlated with a decrease in nNFkB at 50µM FB1 (Figure 4.13). After 72hours 
however, there is an increase in nTG2 (Figure 4.14) with a corresponding significant increase in 
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nTG2 mRNA expression at 10µM FB1(p<0.05) (Figure 4.15) and with a slight decrease in cytosolic 
TG2 at 100µM FB1 (Figure 4.14), evidence for NFkB induction of nTG2 via PERK ER stress 
pathway. Kuo et al. (2012) showed a potential mechanism for TG2-induced apoptosis as a result of 
free fatty acid treatment (Figure 5.1). This mechanism involved the activation of PERK-ER stress 
pathway which induced NFkB activation which then stimulated nTG2 transcription and activation 
leading to apoptosis through its crosslinking of Sp1, a general transcription factor responsible for 
the expression of c-Met an important growth factor (Kuo et al. 2011). Fumonisin B1-treated HepG2 
cells (72hours) showed an activation of both the PERK ER stress pathway and NFkB (Figure 4.13) 
and a subsequent induction of nTG2 (Figure 4.14 and 4.15). Also there was a significant increase in 
Sp1 mRNA at 10µM FB1 (p<0.05) (Figure 4.16) which suggests that Sp1 crosslinking could be a 
potential inducer of FB1-induced apoptosis. However, after 24hours there was a significant 
reduction in Sp1 mRNA expression (p<0.05) (Figure 4.16) suggesting that FB1-induced apoptosis 






Figure 5.1: Schematic diagram illustrating nuclear TG2 induction via the ER stress-mediated PERK 
and NFkB activation which leads to hepatic apoptosis; as a result of free fatty acid treatment of liver 




TG2 has been characterised as an end-stage apoptotic factor where it functions as a crosslinking-
catalytic enzyme that stabilises apoptotic cells prior to phagocytosis (Elli et al. 2009; Fesus & 
Szondy 2005; Park et al. 2010). Various studies have associated TG2 activation and induction with 
apoptosis (Fesus & Szondy 2005; Griffin et al. 2002). The inhibition of ceramide synthase by FB1 
causes an increase in pro-apoptotic factors: sphingosine and sphinganine (Grenier et al. 2012; He et 
al. 2005; Voss et al. 2007). Therefore the apoptotic induction due to FB1 treatment of HepG2 cells 
was investigated. Apoptotic markers were only investigated using the 72hour treatment period 
because it was observed that CHOP (Figure 4.11), a transcription factor that is involved in ER 
stress-mediated apoptosis (Rutkowski & Kaufman 2004) and Sp1 (Figure 4.16) mRNA expression 
were only significantly increased after 72hours (p<0.05). Apoptosis occurs via two pathways: the 
extrinsic/cytoplasmic and intrinsic/mitochondrial pathway. The extrinsic pathway involves Fas 
(member of TNF family) death receptor-induced activation of initiator caspase 8 which activates 
downstream effector caspase 3. The intrinsic pathway involves mitochondrial induction by Bcl-2 
family of proteins (example Bax) to release cytochrome c which binds Apaf-1 resulting in initiator 
caspase 9 activation and forms an apoptosome which activates caspase 3 (Ghobrial et al. 2009). 
Caspases 3/7 (Figure 4.17) and 8 (Figure 4.18) showed a significant decrease in activity at 100µM 
FB1 (p<0.05) and a decrease in caspase 9 (Figure 4.19) activity although not significant. A 
biochemical feature of early stages of apoptosis is the externalisation of PS and depolarised 
mitochondria. After 72hours of 10µM FB1 treatment a significant increase (p<0.05) in PS 
externalisation (Figure 4.21), a significant decrease (p<0.05) in healthy/live cells (Figure 4.22) and 
a significant increase (p<0.05) in depolarised mitochondria (Figure 4.23) were observed. There was 
also a significant increase in Sp1 mRNA expression (p<0.05) in HepG2 cells (Figure 4.16). These 
results show that at a low chronic dose of FB1, apoptosis could be induced via the mitochondrial 
pathway due to a depolarised mitochondrial membrane, however further markers of this pathway 
need to be investigated. However, at 50µM FB1 treatment there is a decrease in PS externalisation 
(Figure 4.21), a significant increase (p<0.05) in live cells (Figure 4.22) and a significant decrease 
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(p<0.05) in depolarised mitochondria (Figure 4.23). This high chronic dose of FB1 is unable to 
induce apoptosis but may cause ER stress to persist as observed by elevated ER stress markers 
previously discussed. The increase in apoptosis as seen by the externalisation of PS shows apoptosis 
is induced; however due to decreased effector caspase 3/7 activity apoptosis is not completed. This 
could possibly be due to increased inhibitors of apoptosis such as inhibitor of apoptosis protein 3, 
however this requires further investigation. 
A summary of the proposed FB1 mechanism of toxicity via the induction of TG2 and the PERK ER 

















A novel interaction between FB1 and TG2 was revealed in this study; confirming FB1 as a high 
affinity substrate for TG2-crosslinked fibronectin. It was demonstrated that FB1-induced ER-stress 
via the PERK pathway. Endoplasmic reticulum stress persisted in HepG2 cells with no apoptosis or 
cell recovery occurring at high chronic doses of FB1 whilst ER stress-induced apoptosis at low 
chronic doses of FB1 in HepG2 cells.  These results confirm for the first time that increased TG2 
activity and expression occurs in HepG2 cells after FB1 treatment which supported the hypothesis. 
The TG2 expression and activation are preliminary data as n=2, therefore require further 
investigation. The study also confirms the activation of the ER stress pathway as a result of FB1 
treatment which supports the second hypothesis. 
This study only researched the PERK arm of the UPR. Future studies could therefore investigate the 
effect of FB1 on the IRE1 and ATF6 arms of the UPR; which could identify possible inducers of 
CHOP. The specific apoptotic pathway induced by low chronic FB1 treatment in HepG2 cells could 
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Figure A1: MethylThiazol Tetrazolium cell viability assay. A significant reduction in cell 
metabolism after 50µM FB1 treatment was observed. The assay was performed on HepG2 cells 
treated with FB1 at varying concentrations over 24hours, wavelength measured at 570nm with a 







Figure A2: CellTiter 96® AQueous One Solution Cell Proliferation assay. A reduction in cell 
viability occurred after 72hours when HepG2 cells where treated with 10µM FB1. The assay was 
performed on HepG2 cells treated with varying concentrations of FB1 for 24, 48 and 72 hours 
measured at wavelength 490nm and reference wavelength 690nm after 1hour incubation at 37°C. 
the data presented is the percentage of cell viability and the associated standard deviations. 
Representative of three separate experiments. 



































































Figure B1: Bicinchoninic acid assay calibration curve used to determine the protein concentration 
of homogenised HepG2 cells treated with 0, 10, 50 and 100µM FB1 for 24hours from known 







Figure B2: Bicinchoninic acid assay calibration curve used to determine the protein concentration 
of homogenised HepG2 cells treated with 0, 10, 50 and 100µM FB1 for 72hours from known 
concentrations of bovine serum albumin. 
y = 0.894x + 0.0674 
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Table B1: Standardisation of protein to 1mg/ml using the calibration curves for sodium dodecyl 






























0 1.707 1.83 1 0.4 0.219 0.181 
10 1.674 1.80 1 0.4 0.222 0.178 
50 1.626 1.74 1 0.4 0.230 0.170 
100 1.641 1.76 1 0.4 0.227 0.173 
72 Hours 
0 1.629 1.68 1 0.4 0.238 0.162 
10 1.495 1.54 1 0.4 0.260 0.140 
50 1.471 1.51 1 0.4 0.265 0.135 










Figure C1: Biotin-cadaverine incorporation into fibronectin – Tissue transglutaminase (TG2) 
calibration curve represented by the absorbance of varying TG2 gpl concentrations (0, 10, 20, 50, 






Figure C2: Biotin-cadaverine incorporation into fibronectin with competitive inhibition by FB1. The 
line graph shows the absorbance values representative of TG2 activity when 100ng/ml gpl TG2 is 
exposed to FB1 concentrations of 0µM, 50µM and 100µM in the presence of calcium. 
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Table D1: The Ct, ΔCt and ΔΔCt values for eIF2 mRNA expression and three housekeeping genes: 
GAPDH, 18s and actin.  
  eIF2 GAPDH ΔCt ΔΔCt 18s ΔCt ΔΔCt Actin ΔCt ΔΔCt 
24 hours 
control 26.507 19.757 6.750 1.000 19.750 6.757 1.000 22.790 3.717 1.000 
10 26.873 19.537 7.337 0.587 19.603 7.270 0.513 22.677 4.197 0.480 
50 26.643 18.933 7.710 0.960 19.153 7.490 0.733 22.090 4.553 0.837 
100 25.723 19.140 6.583 -0.167 19.220 6.503 -0.253 22.860 2.863 -0.853 
72 hours 
control 24.273 19.870 4.403 1.000 19.893 4.380 1.000 22.983 1.290 1.000 
10 24.913 19.257 5.657 1.253 19.270 5.643 1.263 22.187 2.727 1.437 
50 25.070 18.343 6.727 2.323 19.193 5.877 1.497 22.243 2.827 1.537 
100 25.893 19.333 6.560 2.157 20.193 5.700 1.320 23.080 2.813 1.523 
 
Table D2: The Ct, ΔCt and ΔΔCt values for CHOP mRNA expression and three housekeeping 
genes: GAPDH, 18s and actin.  
  CHOP GAPDH ΔCt ΔΔCt 18s ΔCt ΔΔCt Actin ΔCt ΔΔCt 
24 hours 
control 29.153 19.757 9.397 1.000 19.610 9.543 1.000 22.660 6.493 1.000 
10 29.823 19.537 10.287 0.890 19.503 10.320 0.777 22.577 7.247 0.753 
50 28.953 18.933 10.020 0.623 19.103 9.850 0.307 22.190 6.763 0.270 
100 28.343 19.140 9.203 -0.193 19.310 9.033 -0.510 22.600 5.743 -0.750 
72 hours 
control 22.000 19.870 2.130 1.000 19.963 2.037 1.000 22.490 -0.490 1.000 
10 22.953 19.257 3.697 1.567 19.263 3.690 1.653 22.360 0.593 1.083 
50 23.247 18.343 4.903 2.773 19.207 4.040 2.003 22.060 1.187 1.677 




Table D3: The Ct, ΔCt and ΔΔCt values for ATF4 mRNA expression and three housekeeping 
genes: GAPDH, 18s and actin.  
  ATF4 GAPDH ΔCt ΔΔCt 18s ΔCt ΔΔCt Actin ΔCt ΔΔCt 
24 hours 
control 21.673 16.190 5.483 1.000 19.233 2.440 1.000 22.287 -0.613 1.000 
10 21.017 16.253 4.763 -0.720 19.250 1.767 -0.673 22.180 -1.163 -0.550 
50 21.003 16.123 4.880 -0.603 19.143 1.860 -0.580 22.123 -1.120 -0.507 
100 21.917 17.127 4.790 -0.693 20.133 1.783 -0.657 23.057 -1.140 -0.527 
72 hours 
control 24.973 17.063 7.910 1.000 20.047 4.927 1.000 23.053 1.920 1.000 
10 22.487 16.183 6.303 -1.607 19.170 3.109 3.109 22.223 0.056 0.056 
50 21.283 15.713 5.570 -2.340 19.143 2.131 2.131 21.847 -0.572 -0.572 
100 22.530 16.823 5.707 -2.203 19.840 2.687 2.687 22.877 -0.350 -0.350 
 
Table D4: The Ct, ΔCt and ΔΔCt values for TG2 mRNA expression and three housekeeping genes: 
GAPDH, 18s and actin.  
  TG2 GAPDH ΔCt ΔΔCt 18s ΔCt ΔΔCt Actin ΔCt ΔΔCt 
24 hours 
control 29.725 18.856 10.870 1.000 19.153 10.572 1.000 22.363 7.362 1.000 
10 28.835 17.964 10.870 0.001 19.163 9.671 -0.901 22.173 6.661 -0.701 
50 28.406 17.730 10.677 -0.193 19.067 9.340 -1.233 22.347 6.060 -1.303 
100 29.026 18.474 10.552 -0.318 19.830 9.196 -1.376 22.987 6.039 -1.323 
72 hours 
control 28.291 19.241 9.050 1.000 19.677 8.614 1.000 22.077 6.214 1.000 
10 28.119 17.096 11.022 1.972 18.087 10.032 1.418 21.120 6.999 0.784 
50 26.488 17.372 9.116 0.066 18.790 7.698 -0.917 21.613 4.874 -1.340 






Table D5: The Ct, ΔCt and ΔΔCt values for Sp1 mRNA expression and three housekeeping genes: 
GAPDH, 18s and actin.  
  Sp1 GAPDH ΔCt ΔΔCt 18s ΔCt ΔΔCt Actin ΔCt ΔΔCt 
24 hours 
control 25.703 18.856 6.847 1.000 19.863 5.839 1.000 22.920 2.783 1.000 
10 25.689 17.964 7.725 0.878 19.087 6.603 0.763 22.250 3.439 0.657 
50 24.829 17.730 7.099 0.253 19.093 5.736 -0.104 22.147 2.682 -0.100 
100 25.442 18.474 6.968 0.121 19.820 5.622 -0.217 22.890 2.552 -0.230 
72 hours 
control 26.296 19.241 7.055 1.000 20.233 6.063 1.000 23.417 2.879 1.000 
10 25.836 17.096 8.740 1.685 18.697 7.140 1.077 21.883 3.953 1.074 
50 25.040 17.372 7.668 0.613 19.007 6.033 -0.030 22.097 2.943 0.064 















Table E1: The percent of apoptosis after HeepG2 cells were treated with 5µMCampthothecin; a 
positive control for apoptosis. 
Treatment % Apoptosis Mean Standard Deviation 
Campthothecin 28.2 28.2  
Control 10.7 10.8 0.141 












Figure E1: The percentage of apoptosis after HepG2 cells were treated with 5µM Campthothecin; a 





















Table E2: Percentage of depolarised mitochondria after HepG2 cells were treated with 5µM 
Campthothecin; a positive control for apoptosis. 
Treatment Polarised Depolarised Mean Standard Deviation 
Campthothecin 64.9 35.1 35.1  
Control 76.76 23.24 23.42 0.255 









Figure E2: The percentage of depolarized mitochondria after HepG2 cells were treated with 5µM 
Campthothecin; a positive control for apoptosis. 
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